INTERIM CLINICAL GUIDANCE FOR ADULTS WITH CONFIRMED COVID-19 IN BELGIUM

July 2022; Version 2

Preliminary note

COVID-19 is a mild viral illness in the vast majority of the patients (80%) but may cause severe pneumonitis and disseminated endothelitis (1) (and subsequent complications) with substantial fatality rates in elderly and individuals with underlying diseases. About 20% of infected patients need to be admitted, including 5% who require intensive care.

This document is periodically revised to provide support to the diverse groups of Belgian clinicians (general practitioners, emergency physicians, infectious disease specialists, pneumologists, intensive care physicians) who face suspected/confirmed COVID-19 cases during the epidemic in Belgium. This guideline originally targeted primarily hospital care, but as the pandemic has evolved, and more potential treatment options against COVID-19 have emerged, the guideline as of version 26, provides guidance on specific treatments for COVID-19 in the hospital setting, but also in the ambulatory setting. The guideline still refers whenever necessary to other guidelines.

The guidance has been developed from March to December 2020 by a task force of Infectious Diseases Specialists (IDS): Dr Sabrina Van Ierssel, Universitair Ziekenhuis Antwerpen; Dr Nicolas Dauby, Hôpital Universitaire Saint-Pierre Bruxelles; Dr Emmanuel Bottieau, Instituut voor Tropische Geneeskunde (ITG), and Dr Ralph Huits, ITG, supported by Sciensano (Dr Chloe Wyndham-Thomas); the AFMPS/FAGG (Dr Roel Van Loock) and ad-hoc contributions from colleagues of other disciplines. Since January 2021, the COVID-19 therapeutic guideline has officially been taken over by the Belgian Society of Infectiology and Clinical Microbiology (BVIKM/SBIMC), and the new task force is composed of IDS representatives from all Belgian University Hospitals, with the additional collaboration of the Belgian Societies of Intensive Care Medicine and of Pneumology. The complete list of members is available below. This guidance is based on the best clinical evidence (peer-reviewed scientific publications) that is available at the moment of writing each update, and is purposed to be a “living guideline” which can always be found via the same link. Keeping the guideline regularly updated is however particularly challenging due to the incredible speed of knowledge generation for this disease. Readers are warmly invited to send any additional comments, relevant publications, including from the grey literature, and contributions in priority to Dr Maya Hites (maya.hites@erasme.ulb.ac.be) and Dr Emmanuel Bottieau (ebottieau@itg.be). We take this opportunity to thank again the countless readers who, since this guideline was initially released, flagged the inconsistencies, typos or unclear text, as well as those who sent all types of contributions related to this rapidly evolving field.

Of note, this document will not describe in detail the generic and supportive management of COVID-19 (except if there are some pathogen-specific interventions). It is also not aimed at providing an extensive review on all potential investigational treatments in the pipeline.
We have opted for a document with the following structure:

1. **Executive Summary**, with the current therapeutic recommendations for each category of COVID-19 patients, with indications and precautions (Table 1); the strengths of the recommendations are now provided using the GRADE score (2).
2. **The Belgian recommendations for supportive care and adjunctive antiviral/immunomodulatory treatment for suspected/confirmed COVID-19 cases**, detailing latest evidence and rationale behind this consensus.
3. **A summary of the efficacy data of selected antiviral drugs**, clinical evidence for treatment with monoclonal antibodies (Table 2) and *in vitro/in vivo* efficacy of select antiviral drugs (Table 3).
4. **An overview of the ongoing clinical trials in Belgium** (Table 4).
5. **Annexes**
6. **References**

**IMPORTANT**

As a rule, only manuscripts ACCEPTED after a rigorous PEER-REVIEW process will be used for the strong recommendations in this guidance. Important (pre-publication) communications by well-established research groups will be however mentioned if the findings may strongly impact the clinical care within a rather short timeframe.

Use of off label or investigational antiviral or immunomodulatory drugs should be reserved to clinical studies/trials only and efforts are undertaken by the KCE to support non-commercial multicentric studies in Belgium. In addition, use of standardized case report forms is strongly encouraged during patient management, in order to obtain rapid feedback on safety issues and patient outcomes.

**Members of the working group**

- Koen Blot: Dept. of Epidemiology and Public Health, Sciensano
- Emmanuel Bottieau: Dept of Clinical Sciences, Instituut voor Tropische Geneeskunde (ITG)
- Nicolas Dauby: Dept. of Internal Medicine and Infectious Diseases, CHU-Saint-Pierre
- Julien De Greef: Dept. of Internal Medicine and Infectious Diseases, Clin. Univ. Saint-Luc-UCLouvain
- Pieter Depuydt: Dept. of Intensive Care Medicine, UZ Gent
- Paul De Munter: Dept. of Internal Medicine, UZ Leuven
- Maya Hites: Clinic of Infectious Diseases, Hôpitaux Universitaire de Bruxelles (HUB)-Erasme
- Patrick Lacor: Dept. of Internal Medicine, UZ Brussel
- Natalie Lorent: Dept. of Pneumologie, UZ Leuven
- Jiska Malotaux: Dept. of Internal Medicine, UZ Gent
- Fabio Taccone: Dept. of Intensive Care Unit, CUB-Erasme
- Caroline Theunissen: Dept. of Clinical Sciences, ITG
- Eva Van Braeckel: Dept. of Respiratory Medicine, UZ Gent
- Sabrina Van Ierssel: Dept. of Internal Medicine, UZ Antwerpen
- Roel Van Loock: DG PRE – Dept. of Assessors, FAGG - AFMPS
- Sandrine Milas: Dept. Infectious Diseases CHU Charleroi
- Sophie Servais: Dept. Of Hematology, CHU Liege
- Emmanuel André : Dept. Of Medical Microbiology, UZ Leuven

A conflict of interest list for the members is available [here](#).
1. Executive summary

Table 1: Supportive care & antiviral/immunomodulatory therapies for prevention in immunosuppressed patients and treatment of COVID-19 in hospitalized patients

<table>
<thead>
<tr>
<th>Clinical category</th>
<th>Supportive Care</th>
<th>Additional therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prophylaxis against COVID-19</td>
<td>Preventive treatment in adjunction to vaccination</td>
<td>mAbs (Evusheld®) should be proposed to severely immunocompromised patients (conditional recommendation, low quality of evidence in this patient population).</td>
</tr>
<tr>
<td>Confirmed mild or moderate COVID-19</td>
<td>Symptomatic treatment</td>
<td>mAbs that demonstrate strong <em>in-vitro</em> activity against circulating SARS-CoV2 strains should be proposed to patients at high risk for complications after balancing individual risks and benefits within a hospital multidisciplinary team (Strong recommendation, moderate quality of evidence – 1B). If <em>in-vitro</em> activity is poor, the mAB should not be administered. This is currently the case with Omicron BA.5 sub-variant. Follow the algorithm to assess eligibility criteria for treatment with mAbs for adult patients with mild or moderate COVID-19 infection. Antivirals should be proposed to severely immunocompromised patients, at high risk of progressing to severe disease ONLY if monoclonal antibodies (mAbs) have a significantly <em>in-vitro</em> decreased efficacy against circulating VOC, and in the following order:</td>
</tr>
<tr>
<td>➢ Mild disease: symptoms of COVID-19 without lower respiratory tract involvement such as dyspnea or abnormal chest imaging</td>
<td></td>
<td>Nirmatrelvir/ritonavir (Paxlovid®, oral), for 5 days, after careful evaluation of drug-drug interactions (conditional recommendation, low quality of evidence.)</td>
</tr>
<tr>
<td>➢ Moderate disease: clinical or radiological evidence of lower respiratory tract disease and SpO2 ≥94% or does not require supplemental oxygen</td>
<td></td>
<td>Remdesivir (Veklury®, IV) for 3 days (conditional recommendation, low quality of evidence)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Molnupiravir (Lagevrio®, oral), for 5 days, only if patients present a creatinine clearance of &lt; 30 mL/minute, thus excluding them from the possibility of receiving Paxlovid®, or Veklury®. (conditional recommendation, low quality of evidence.)</td>
</tr>
</tbody>
</table>

The safety and efficacy of these treatments have hardly been evaluated in immunocompromised patients. No real life data is available concerning current circulating Variants of Concern (VOC).
<table>
<thead>
<tr>
<th>Confirmed COVID-19 severe disease</th>
<th>Optimal supportive care in hospital WARD (or ICU)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 1 of the following:</td>
<td>Provide O₂</td>
</tr>
<tr>
<td>➢ Respiratory rate ≥30/min (adults); ≥40/min (children &lt; 5y)</td>
<td>Administer LMWH according to BSTH guidelines, if not contra- indicated</td>
</tr>
<tr>
<td>➢ Blood oxygen saturation ≤93% or requires supplemental oxygen</td>
<td>Carefully consider antibiotics or antifungals according to local epidemiology</td>
</tr>
<tr>
<td>➢ PaO₂/FiO₂ ratio &lt;300</td>
<td></td>
</tr>
<tr>
<td>➢ Lung infiltrates &gt;50% of the lung field within 24-48 hours</td>
<td></td>
</tr>
</tbody>
</table>

**Dexamethasone** 6 mg once a day for up to 10 days (or until hospital discharge, if sooner), IV or PO; (Strong recommendation, high-quality evidence - 1A).
If dexamethasone is not available, equivalent doses of corticosteroids can be used (hydrocortisone 150 mg/d or methylprednisolone 32 mg/d or prednisone 40 mg/d) (Strong recommendation, moderate quality of evidence - 1B). Case by case decision for children and pregnant women pending additional results and with the respective specialists.

**Tocilizumab and other interleukin-6 blockers:** consider early administration of IL6-receptor antagonists (tocilizumab 8 mg/kg IV with a maximum of 800 mg) in addition to corticosteroids in hospitalized patients with rapidly progressive COVID-19 (Conditional recommendation, moderate quality of evidence - 1B), as long as there is availability of the drug (after prioritizing the drug for patients with cytokine release syndrome caused by chimeric antigen receptors T-cell medicines, giant cell arteritis, systemic juvenile idiopathic arthritis, juvenile idiopathic polyarthritis, and severe rheumatoid arthritis), and taking into account that there is currently no reimbursement for the COVID-19 indication in Belgium.

A higher dose of dexamethasone (12 mg once a day) may be considered in patients with high needs in oxygen (≥10L/min or High Flow Oxygen Therapy (HFOT)), who are not receiving tocilizumab (weak recommendation, low quality of evidence).

**Baricitinib:** Consider the addition of baricitinib (4mg twice daily for up to 14 days) in hospitalized patients with COVID-19 pneumonia (conditional recommendation, low certainty of evidence).

**Tofacitinib:** Consider the addition of tofacitinib (10mg twice daily for up to 14 days) in hospitalized patients with pneumonia, when IL-antagonists and baricitinib are not available, after balancing individual risks (including a possible increased risk of thromboembolic events) and benefits (conditional recommendation, low certainty of evidence). Current data suggests potential increase in adverse events in patients treated with tofacitinib.
<table>
<thead>
<tr>
<th>Clinical category</th>
<th>Supportive Care</th>
<th>Additional therapy (Strength of recommendation - GRADE)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Confirmed COVID-19 critically ill disease</strong></td>
<td></td>
<td><strong>Dexamethasone</strong> 6 mg IV (or equivalent doses of corticosteroids, see row above) once a day for up to 10 days; case by case decision for children and pregnant women pending additional results and with the respective specialists (Strong recommendation, high-quality evidence - 1A).</td>
</tr>
<tr>
<td>≥ 1 of the following:</td>
<td>Optimal supportive care in ICU</td>
<td></td>
</tr>
<tr>
<td>➢ Acute Respiratory Distress Syndrome</td>
<td>Mechanical ventilation</td>
<td></td>
</tr>
<tr>
<td>➢ Sepsis</td>
<td>Administer LMWH according to BSTH guidelines, if not contra-indicated</td>
<td></td>
</tr>
<tr>
<td>➢ Altered consciousness</td>
<td>Specific prevention &amp; treatment of ARDS</td>
<td></td>
</tr>
<tr>
<td>➢ Multi-organ failure</td>
<td>Track secondary bacterial and opportunistic (Aspergillus) infections</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Prevention of subsequent lung fibrosis</td>
<td></td>
</tr>
</tbody>
</table>

**ARDS:** Acute respiratory distress syndrome. **LMWH:** low molecular weight heparin

**Tocilizumab and other interleukin-6 blockers:** Consider early administration of IL6-receptor antagonists in addition to corticosteroids in hospitalized patients with rapidly progressive COVID-19 (Conditional recommendation, moderate quality of evidence -1B), as long as there is availability of the drug (after prioritizing the drug for patients with cytokine release syndrome caused by chimeric antigen receptors T-cell medicines, giant cell arteritis, systemic juvenile idiopathic arthritis, juvenile idiopathic polyarthritis, and severe rheumatoid arthritis), and taking into account that there is no current reimbursement for the COVID-19 indication in Belgium.

**A higher dose of dexamethasone** (12 mg once a day) may be considered in patients with high oxygen needs (≥10L/min or HFOT) or mechanical ventilation, who are not receiving tocilizumab (weak recommendation, low quality of evidence).
Precautions of use & additional information

**General:** Use paracetamol in first-line (usual dosage), and NSAIDs with caution (if really required)

**Dexamethasone:** Usual contraindications. It is currently unknown whether the use of corticosteroids in COVID-19 is independently associated with an increased risk for bacterial or fungal infections. The use of dexamethasone may reduce the discriminatory potential of C-reactive protein (CRP) and procalcitonine (PCT) as biomarkers for the diagnosis of secondary bacterial infection (see comments).

**Monoclonal antibodies (mAbs):** Treatment is authorized by the EMA, but they are not commercially available. In Belgium, mAbs can only be administered in the hospital setting, after authorization by a multidisciplinary team including at least an infectious disease physician.

- **Warning/precautions:**
  - Intrinsic resistance or decreased *in-vitro* neutralisation has to be considered (please see Table 2, below).
  - Health care providers must have immediate access to medications to treat a severe infusion reaction, such as anaphylaxis. Patients should be observed for at least one hour following infusion completion.
  - Subcutaneous route should only be used when intravenous route is not feasible and will result in treatment delay (only for casirivimab+imdevimab).
  - Renal impairment: No dosage adjustment is required in patients with altered kidney function (including those on dialysis) or for geriatric patients.
  - Hepatic impairment: mAbs have not been studied in individuals with severe hepatic impairment.
  - Cardiovascular events: A higher proportion of individuals who received tixagevimab/cilgavimab (EVUSHELD®), compared to placebo reported myocardial infarction and cardiac failure serious adverse events in the TACKLE and PROVENT trials. All patients had cardiac risk factors and/or prior history of cardiovascular disease. When giving this treatment for prophylaxis, weigh risks and benefits of this treatment in patients with cardiovascular risk factors (link).
  - Pregnancy: The risk of severe COVID-19 is increased in pregnant women and COVID-19 infection increases risks for adverse pregnancy outcomes. mAbs should be used during pregnancy only if the potential benefit justifies the potential risk for the mother and the foetus, considering all associated health factors.

- **Interactions:**
  - mAbs could interfere with the immune response to COVID-19 vaccination and CDC recommends deferring vaccination for at least 90 days after receiving mAbs.
  - In individuals who have received a COVID-19 vaccine, preventive tixagevimab+ cilgavimab (EVUSHELD®) should be administered at least two weeks after vaccination.

- **Contraindications:**
  - Hypersensitivity to monoclonal antibodies or to any of the excipients.
Table 2: Neutralisation activity of monoclonal antibodies (mAbs) available in Belgium against the main SARS-CoV-2 Variants of Concern (VOC) (3,4).

Information on the VOC currently circulating in Belgium can be accessed via "Genomic Surveillance of SARS-CoV-2 in Belgium" (link).

<table>
<thead>
<tr>
<th></th>
<th>Delta B.1.617.2</th>
<th>Omicron BA.1 B.1.1.529</th>
<th>Omicron BA.2 BA. Lineage</th>
<th>Availability in Belgium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Casirivimab (REGN10933)</td>
<td>Maintained activity</td>
<td>Highly reduced activity</td>
<td>Highly reduced activity</td>
<td>/-</td>
</tr>
<tr>
<td>Imdevimab (REGN10987)</td>
<td>Maintained activity</td>
<td>Highly reduced activity</td>
<td>Reduced (to highly reduced) activity</td>
<td>/-</td>
</tr>
<tr>
<td>Ronapreve® (casirivimab+imdevimab)</td>
<td>Maintained activity</td>
<td>Highly reduced activity</td>
<td>reduced activity (to highly reduced activity)</td>
<td>Out of federal stock in November 2021</td>
</tr>
<tr>
<td>Sotrovimab (S309), Xevudy®</td>
<td>Maintained activity</td>
<td>Maintained activity</td>
<td>Highly reduced activity</td>
<td>Available via federal stock</td>
</tr>
<tr>
<td>Tixagevimab (AZD8895)</td>
<td>Maintained activity</td>
<td>Highly reduced activity</td>
<td>Highly reduced activity</td>
<td>/-</td>
</tr>
<tr>
<td>Cligavimab (AZD1061)</td>
<td>Maintained activity</td>
<td>Highly reduced activity</td>
<td>Maintained activity</td>
<td>/-</td>
</tr>
<tr>
<td>Evushel® AZD7442</td>
<td>Maintained activity</td>
<td>Highly reduced activity</td>
<td>(Slightly) reduced activity. Activity essentially maintained by Cligavimab.</td>
<td>Available since 20 April 2022 via federal stock, for prophylactic use only</td>
</tr>
<tr>
<td>Tociluzimab and Anakinra:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Caution must be exercised when used in patients with active concomitant (myco-) bacterial and fungal infections and in chronically immunosuppressed patients. Alternative inflammatory markers instead of CRP (such as procalcitonin) may be used to monitor supra-infections in patients treated with IL-6 or 1 blockers.
Remdesivir (Veklury®):
- **Contraindications:**
  - Hypersensitivity to active substance(s) or any of excipients
- **Warnings/precautions:**
  - **Hepatic impairment:** Remdesivir should only be used in patients with hepatic impairment if the potential benefit outweighs the potential risk. Remdesivir should not be initiated in patients with ALT ≥ 5 times the upper limit of normal at baseline.
  - **Renal impairment:** Pharmacokinetics of remdesivir has not been extensively evaluated in patients with renal impairment. In patients with eGFR < 30mL/min, the benefits & risks are to be weighed.
  - **Possible bradycardia:** Post-marketing study based on the World Health Organization pharmacovigilance database identified increased reports of serious bradycardia among patients treated with remdesivir. Remdesivir was the sole suspected drug among 93% of 88 patients (6). Following Pharmacovigilance Risk Assessment Committee (PRAC) advice, EMA has recommended to include bradycardia as a possible side-effect of Veklury (link).
- **Interactions:**
  - Strong inducers of CYP2C8, CYP2D6 and CYP3A4 (e.g. rifampicin) may decrease plasma concentrations and are not recommended.
  - Co-administration of remdesivir with CYP1A2 or CYP3A4 substrates with narrow therapeutic index may lead to loss of their efficacy.
  - Still limited information on drug interactions is available. Risk-benefit assessment should be made individually. Close monitoring of remdesivir toxicity or diminished efficacy of concomitant drugs is recommended. Check also for interactions with remdesivir at the drug-drug interactions on the University of Liverpool website (link).
- More information on warnings/precautions of use in [Veklury product information](https://rdvcu.gilead.com/).
- Registered for treatment of COVID-19 in adults and adolescents from 12 years of age (with at least a body weight of 40kg). For pregnant women & children: compassionate use is possible, request on [https://rdvcu.gilead.com/](https://rdvcu.gilead.com/).

Lagevrio® (Molnupiravir)
- **Warnings/precautions:**
  - No significant effect in sero-positive patients for SARS-CoV2.
  - Low estimated risk of mutagenicity.
Possible bone and cartilage malformations identified in animal experiments. The drug is therefore contraindicated during pregnancy and is only approved by the EMA for use in individuals ≥ 18 years old.
Paxlovid® (Nirmatrelvir+ritonavir)

- **Warnings/precautions:**
  - For moderate renal impairment (eGFR ≥ 30 to < 60 mL/min): dose reduction to 150 mg of nirmatrelvir + 100 mg ritonavir.
  - PAXLOVID is not recommended in patients with severe renal impairment (eGFR <30 mL/min)
  - PAXLOVID is not recommend in patients with severe hepatic impairment (Child-Pugh Class C)
  - Hepatic transaminase elevations have occurred in patients receiving ritonavir
  - There are no available human data on the use of nirmatrelvir during pregnancy

- **Interactions:**
  - **Ritonavir is a strong cytochrome P450 3A4 inhibitor,** therefore Paxlovid should not be co-administered with drugs highly dependent on CYP3A or with potent CYP3A inducers. Check drug-drug interactions on the University of Liverpool website (link) and EMA (link)

**General statement on anti-viral drugs:** The current available antiviral drugs have not been extensively evaluated for safety and efficacy in all patient populations. Furthermore, the current circulating SARS-CoV2 variants are different than those circulating when the drugs were evaluated in clinical trials. Therefore, it is very important to keep on monitoring the efficacy and the safety of these different antivirals in different patient populations. Clinicians should record whether patients have been cured or not of their COVID-19. Virological follow-up of patients should be performed and persisting positive nasopharyngeal samples for SARS-CoV2 should be sent to the National Reference Center for further analysis. We will be proposing a standardized case report form with virological follow-up in a near future. We would encourage all clinicians to participate actively in collecting and sharing this information!
### Availability of antivirals for COVID-19 in Belgium

<table>
<thead>
<tr>
<th>Name</th>
<th>Availability in Belgium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molnupiravir (Lagevrio®)</td>
<td>Currently available via the federal stocks only for utilization in the nursing home or hospital setting in the case of a COVID-19 outbreak, or if contraindication to receive other antivirals, or in the context of a clinical trial: <a href="https://kce.fgov.be/nl/task-force-covid-therapeutics/lagevrio-toegangsmogelijkheden">https://kce.fgov.be/nl/task-force-covid-therapeutics/lagevrio-toegangsmogelijkheden</a></td>
</tr>
<tr>
<td>Remdesivir (Veklury®)</td>
<td>Available via hospital pharmacies, via the federal stocks.</td>
</tr>
</tbody>
</table>
2. Belgian recommendations for supportive care and adjunctive antiviral/immunomodulatory treatment for confirmed COVID-19 cases.

As summarized in the executive summary table, we recommend that dexamethasone (or if not available, equivalent doses of corticosteroids) be considered as standard of care in severe and critical COVID-19 disease (grade 1A). Background data and rationale behind these recommendations are detailed here. Latest results concerning additional antiviral and immunomodulatory treatments are also covered hereunder.

Additional notes are also given on ACE inhibitors/ARBs, pregnant women, children, anticoagulation, oxygen therapy and ambulatory care.

2.0. CORTICOSTEROIDS

2.0.0. Dexamethasone, systemic corticosteroids

Main message: Systemic corticosteroids (dexamethasone) are recommended for COVID-19 patients with severe disease. In case dexamethasone is not available, the WHO recommends using equivalent doses of other corticosteroids (7). See Executive summary Table 1 for details.

Available evidence in the hospital setting: Although treatment with systemic corticosteroids was initially not recommended (8)(9), the availability of high-quality evidence demonstrates a reduction in mortality among COVID-19 patients with severe disease. Low dose dexamethasone (6 mg/day once daily for 10 days) is a treatment option which has been investigated in one of the UK-RECOVERY study arms. In this study, dexamethasone significantly reduced the overall 28-day mortality rate (age-adjusted rate ratio, 0.83 [95% CI 0.75 to 0.93]; P=0.001) (10). In a pre-specified subgroup analysis according to the level of respiratory support that the patients were receiving at randomization, there was a trend showing the greatest absolute and proportional benefit among patients who were receiving invasive mechanical ventilation (11.5 by chi-square test for trend). Compared with standard of care, dexamethasone reduced incidence of death in ventilated patients (29.3% vs. 41.4%, rate ratio 0.64 [95% confidence interval 0.51 to 0.81]) and in other patients receiving oxygen only (23.3% vs. 26.2%, 0.80 [0.70 to 0.92]). No evidence of benefit for patients who did not require oxygen was found, and patients outside the hospital setting were not included in the study. In a subgroup analysis, dexamethasone was associated with a reduction in 28-day mortality among those with symptoms for more than 7 days but not among those with more recent symptom onset (12.3 by chi-square test for trend). Based on this survival benefit in the sickest patients, the manageable toxicity of low-dose/short-course dexamethasone in hospitals and the strong biological plausibility of an anti-inflammatory treatment in the second phase of COVID-19 infection, the Belgian Clinical Treatment Guidelines task force has recommended since version 12 low-dose dexamethasone for admitted patients requiring oxygen, in particular requiring mechanical ventilation and with a symptom onset > 7 days. Following the publication of the RECOVERY results, three other large RCTs evaluating various doses and types of steroids in critical COVID-19 stopped patient inclusion prematurely before reaching the respective target sample sizes, i.e. REMAP-CAP (multicountry) (11), CoDEX (Brazil) (12), and CAPE COVID (France) (13). The results of RECOVERY, of the last 3 published (“incomplete”) RCTs and of another three ongoing smaller trials were then pooled and meta-analyzed by the WHO REACT working group (7). The conclusion was robust throughout all trials (n=678 in total versus 1025 in placebo/usual care arm, all critically ill patients): administration of systemic corticosteroids in
critically ill patients with COVID-19 is associated with decreased 28-day mortality (0.66 (95% CI 0.53-0.82; p<0.001). This association was similar for dexamethasone and hydrocortisone, for higher versus lower doses of steroids, and in admitted patients with fewer or greater than 7 days of symptoms, requiring oxygen either through mechanical ventilation or not. While exact details concerning the implementation in clinical practice is lacking, the consistent findings of benefit provide definitive data that corticosteroids should be first-line treatment for critically ill patients with COVID-19 (14). A recent study confirmed that corticosteroids should not be administered to hospitalized patients with COVID-19 who do not require oxygen. Indeed, in an observational cohort of 19,973 patients admitted to the hospital within 14-days of a positive PCR or antigen test for SARS-CoV2, an inverse probability of treatment weights was used to balance exposed to unexposed groups, and a Cox proportional hazards model was used to determine 90-day all-cause mortality. Patients on no oxygen who received dexamethasone had a 76% increased risk for 90-day mortality (HR 1.76, 95% CI 1.47 to 2.12) (15).

A living Cochrane Systematic Review and Meta-Analysis on the use of systemic corticosteroids in COVID-19 thus far included 11 RCTs in 8075 participants but restricted outcome analysis to 9 RCTs (up to date until April 2021). The main conclusions were that systemic corticosteroids plus standard care as compared to standard care alone probably reduced all-cause mortality slightly (risk ratio 0.89 (CI 0.80-1.00) and may increase ventilator-free days (mean difference 2.6d, CI 0.7-4.5) (16). Importantly, 42 ongoing studies and 16 studies reported completed or terminated without yet published results were identified, suggesting that effect estimates and certainty of the evidence may change in the future.

The COVID STEROID 2 trial randomized 1000 patients with severe to critical COVID-19 (supplemental oxygen with a flow rate of at least 10L/min or receiving mechanical ventilation) between 6mg and 12mg dexamethasone. In the 12mg dexamethasone group, median number of days alive without life support (adjusted mean difference -1.3d (0-2.6)) and 28-mortality (adjusted relative risk 0.86 (0.68-1.08)) were lower. Although both endpoints failed to reach statistical significance, the accompanying editorial suggested a clinically meaningful treatment effect of higher dose corticosteroids in more severely ill COVID-19 patients [COVID STEROID 2 Trial Group. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia (17,18). In addition, a pre-planned Bayesian analysis of the COVID STEROID 2 trial data found high probabilities of benefit and low probabilities of clinically important harm with dexamethasone 12mg versus 6mg up to 60 days after inclusion. Longer term outcome, as expressed by mortality and health-related quality of life at 180 days, was however not significantly different between higher and standard dose dexamethasone groups, although the results were again mostly compatible with a benefit from 12mg, and an absolute 3% or more increase of mortality could be rejected with 99% certainty (19). Finally, the results of the COVID STEROID 2 trial raise the possibility that benefit from IL-6 receptor antagonists may be less substantial when co-administered with this higher dose of corticosteroids, as mentioned in the same editorial (18).

Additional studies comparing different doses of corticosteroids in COVID-19 have been published. A randomized monocentric trial carried out in Iran in 144 hospitalized patients with moderate to severe COVID-19 evaluated the efficacy and safety of different doses of dexamethasone (8 mg once daily, 8 mg twice daily, and 8 mg three times daily for up to 10 days or hospital discharge). Higher doses of dexamethasone resulted in an increase in adverse events, a lower clinical response, and shortened survival compared to lower doses of dexamethasone (20). A multicenter RCT randomized 546 patients between standard (6mg) and high (20mg) dose dexamethasone and different oxygenation strategies (low flow oxygen, high flow oxygen and CPAP) in a 2x3 factorial design; no differences in 60-day mortality were observed between patients receiving 6mg versus 20mg dexamethasone (21).
A pilot RCT was done using biomarker (CRP) guided approach to steroid dosing. Forty-one patients were included: 19 in the intervention arm, and 22 in the usual care arm. The study was ongoing when the results of the RECOVERY trial were published. After that the patients in the standard of care arm received a fixed dose of steroids. Only 50% of the patients in the usual arm received steroids. When only patients on steroids were analyzed, the intervention arm (n=17) had less cumulative steroid exposure [median 122 (102.0, 160.0) versus 256 (128, 320) mg, p=0.005], more oxygen-free days [23 (20, 25) versus 17 (8, 22), p=0.032] and no difference in hospital-free days [21 (18, 22) versus 17 (7, 21), p=0.06] than the usual care arm (n=11). The study showed that the CRP-based dosing was feasible and safe. A large (multicenter) RCT is warranted to be able to determine an effect on patient outcome (22).

**Notes on treatment with systemic corticosteroids:** It is currently unknown whether the use of corticosteroids in COVID-19 is independently associated with an increased risk for bacterial or fungal infection. A systematic review with meta-analysis complemented the 7 RCTs analyzed in (7) with 37 retrospective observational studies, covering 20,197 patients (25). Diverse corticosteroid regimens were investigated, most of which consisted of methylprednisolone; 16/29 and 11/29 studies used respectively high (>1mg/kg prednisolone) and lower (<1mg/kg prednisolone) doses. A trend towards more antibiotic use and more infections (6 studies) was noted; however overall pooled estimates showed a reduced mortality in the corticosteroid-treated patients (OR 0.72; 0.57-87), which is in a range similar to that found in the WHO REACT working group meta-analysis (7). A prospective study with serial assessment of C-reactive protein (CRP) and procalcitonin (PCT) in COVID-19 patients found a lower discriminative value of both biomarkers for the early detection of secondary bacterial infections in patients treated with dexamethasone with and without tocilizumab (26).

The risk versus benefit of late corticosteroid therapy in patients with COVID-19 associated ARDS is currently not known. A post-hoc analysis of a multicenter dataset of 348 patients with moderate to severe ARDS associated with COVID-19 admitted to 21 French and Belgian ICUs, comparing with and without corticosteroid-treatment after 13 days of symptom onset did not find a difference in ICU mortality (HR 1.44; 0.83-2.50) or duration of mechanical ventilation (HR 0.89; 0.60-133) (27). No studies have addressed the question whether a prolonged course or a second course of corticosteroids influence the outcome in COVID-19 patients who remain ventilator dependent following a standard course of corticosteroids as provided in the RCTs. A systematic review and trial sequential meta-analysis was performed analysing the use of corticosteroids in patients with ARDS due to COVID-19 and non-COVID-19 related etiology. The use of corticosteroids was found to probably reduce 28-d mortality (RR 0.82; 0.72-0.95) regardless of etiology, and to probably reduce the duration of mechanical ventilation (mean difference 4d fewer, 2.5-5.5), but the optimal information size was not reached in the trial sequential analysis. Among the pooled analysis of COVID-19 and non-COVID-19 patients, those who received >7d of corticosteroids had lower mortality than those who received a ≤7d course (p=0.04) (28).
Effects of low-dose and short-course corticosteroids on risk of *Strongyloides* reactivation is not well known. Nevertheless, for high-risk patients, such as those originating from *Strongyloides* endemic areas, empirical ivermectin treatment should be considered before, or early during, corticosteroid treatment (29).

**Available evidence in the ambulatory setting:** While exact details concerning the implementation in clinical practice is lacking, the consistent findings of benefit provide definitive data that systemic corticosteroids should be first-line treatment only for severely and critically ill patients with COVID-19 (14).

### 2.0.1. Inhaled corticosteroids

**Available evidence in the hospitalized setting:** No data

**Available evidence in the ambulatory setting:** The possible benefit of inhaled corticosteroids in early COVID-19 (<7 days after symptom onset) was investigated in a phase-II open label RCT in the UK (30). The trial was stopped early because of a reduced number of new cases. Independent statistical review concluded that the study outcome would not change with further participant enrolment. The patients in the budesonide group had a significantly lower probability of an urgent care visit (15% vs 3%). The number needed to treat to avoid an urgent care visit was eight. Self-reported clinical recovery was shortened by 1 day (median 7 days [95% CI 6–9] vs 8 days [7–11]; log-rank test p=0.007). This is the first published trial evaluating inhaled corticosteroids in COVID-19. Several similar trials are still ongoing.

The PRINCIPLE trial investigated 2x800µg inhaled budesonide added to usual care in (suspected) COVID-19 patients in the community, aged ≥65y or ≥50y with co-morbidities and ≤14d symptoms. The study ran from November 2020 until March 2021 and included 4700 participants; a Bayesian primary analysis model included data from 2530 patients with confirmed COVID-19. This analysis found a shorter time to self-reported recovery (minus 3d; CI: 1-5.4) in the budesonide arm, as well as a lower rate of hospital admission or death (2%, -0.2-4.5%), the latter without however reaching the prespecified threshold of superiority. In prespecified subgroup analyses, the budesonide effect was not modified by symptom duration before randomization, baseline symptom severity, age or comorbidities. Few serious adverse events were reported, and there was no observed difference between the budesonide group and the usual care group (31).

Results of a phase-III RCT placebo-controlled trial on inhaled ciclesonide, including 400 non-hospitalized patients with symptomatic COVID-19, showed no significant difference in time to alleviation of COVID-19 related symptoms (primary endpoint) although a reduction in the number of hospitalizations or emergency department visits was observed in one of the secondary endpoints (32).

The CONTAIN trial is a phase II placebo controlled RCT on inhaled ciclesonide in patients with predominantly respiratory symptoms (fever, cough, dyspnea). The trial was stopped early because of dropping numbers of new inclusions when the rate of vaccination was rapidly increasing. 203 patients were included in the modified intention-to-treat population, randomised 1:1 inhaled an intranasal ciclesonide vs placebo. There was no statistical difference in symptom resolution on day 7, the primary endpoint (40% vs 35%, absolute adjusted risk difference 5.5% (95% confidence interval −7.8% to 18.8%)). The trial included mostly young people without comorbidities who are already a low-risk population. It is also possible that the study was underpowered to show significant results because it was stopped early. Currently however there is insufficient evidence to support the use of inhaled steroids (33). The COVERAGE trial is another open-label, RCT in
outpatients with documented COVID-19 with risk factors for aggravation, and with symptoms for \( \leq 7 \) days where patients were randomized to the control arm or other treatment arms, one of which was inhaled ciclesonide. In this arm of the trial, there were 217 participants, all with at least one co-morbidity. No significant difference was observed in the intention-to-treat population in reaching the primary end-point of COVID-19 worsening by day 14 (12/106 (11.3%, 95% CI: 6 to 18.9%) in the control arm vs. 14/106 (13.2%, 95% CI: 7.2 to 21.2%) in the ciclesonide arm (34).

A meta-analysis including four RCTs on the use of inhaled corticosteroids in outpatients with COVID-19 found a significant effect on the resolution of symptoms at day 14, although this was smaller in the placebo-controlled studies as compared to the open label studies; a reduced probability of hospitalization with inhaled corticosteroids was only observed in the open label studies, suggesting an important placebo effect (35).

In advice dated on 27/5/2021, the EMA considered the evidence published thus far as insufficient to recommend the use of inhaled corticosteroids in COVID-19, as the possibility of causing harm to patients not requiring additional oxygen, cannot as yet be excluded (link).

2.1. REMDESIVIR

Main message: The WHO issued a conditional recommendation against the use of remdesivir (RDV) in hospitalized patients, regardless of the severity, as there is currently no evidence that remdesivir improves survival and other outcomes in these patients. Moreover, all studies in humans have demonstrated an absence of antiviral effect in hospitalized COVID-19 patients. As dexamethasone is now considered the standard of care for hospitalized patients requiring oxygen or on mechanical ventilation, it is important to highlight that there is almost no data on the impact of combining dexamethasone and RDZ on clinical outcomes.

Available evidence in the hospital setting: RDV seemed promising in vitro and in non-human primate models (36). An initial Chinese trial did not show any survival benefit with RDV, but the study could not include enough cases and was discontinued at the end of the local epidemic (37). In this study (where median delay from symptom onset to enrolment was quite long, 11 days in the RDV group), there was no effect of RDV on viral load over time in both upper and lower respiratory tract specimens, suggesting the absence of antiviral effect.

A final report of the ongoing NIAID-ACTT NCT04280705 trial conducted in the US was published (38) confirming a faster recovery in RDZ-treated hospitalized COVID-19 patients with evidence of pneumonia (n=541) compared to patients given placebo (10 days instead of 15 days; recovery rate ratio 1.29; [95% CI 1.12 to 1.49], p<0.001). The benefit was most apparent in those COVID-19 patients receiving low-flow oxygen, the largest group of patients included in the study, and when RDZ was given before the 10th day of symptom onset. Results were not conclusive for other groups of patients (those not requiring supplemental oxygen, or in patients requiring mechanical ventilation). No statistical difference was seen for mortality by Day 15 (6.7% mortality versus 11.9%) and by Day 29 (11.4 versus 15.2%), but there was a positive trend compared to placebo (hazard ratio: 0.73 95% CI 0.52 to 1.03).

In addition, a randomized, open-label, phase 3 trial, comparing 5-day and 10-day treatment with RDZ in patients with severe/critical disease (oxygen requirement), did not find a significant difference in efficacy between these two treatment durations. After adjustment for baseline imbalances in disease severity (patients assigned to 10-day course had significantly worse clinical status than those in the 5-day group), outcomes were similar as measured by a number of end points: clinical status at day 14, time to clinical improvement, recovery, and death from any cause. Post-hoc analysis showed that patients receiving
mechanical ventilation or ECMO may benefit from 10 days of RDZ treatment. Further evaluation of this subgroup and other high-risk groups, such as immunocompromised persons, is needed to determine the shortest effective duration of therapy in these patients (39).

A third RCT sponsored by Gilead (Spinner et al.) assessed the role of RDZ in hospitalized patients with non-severe COVID-19 (not requiring oxygen supplementation) (40). The patients (n=584) were randomized 1:1:1 to 10-day course of RDV, 5-day course of RDV and standard of care. Mortality was low (1%). A better clinical status on day 11 after treatment initiation was observed with the 5-day course but not the 10-day course. The clinical significance of this finding remains uncertain as the patients in the 5-day and 10-day courses received almost the same number of doses of RDZ (5 and 6, respectively).

It is important to highlight that in both the ACTT-1 and Spinner trials, no impact of RDV on viral shedding was reported. In both trials, the median duration of symptoms before enrollment was 9 days, limiting the potential for a significant antiviral effect as was also observed in the Wang et al. trial (37).

In December 2020, results from the SOLIDARITY multicenter worldwide pragmatic trial were published, showing no overall clinical benefit of RDZ in hospitalized patients with COVID-19. RDZ was evaluated in 2743 patients, compared to 2708 controls. In a meta-analysis of the 4 published trials on RDZ, a weighted average of the results from all trials yielded a rate ratio for death (RDZ vs. control) of 0.91 (95% CI, 0.79 to 1.05). However, in the subgroup of patients receiving no mechanical ventilation at time of randomization, the rate ratio for death was 0.80 (0.63-1.01) (41). The WHO issued a conditional recommendation against the use of RDZ in hospitalized patients, regardless of the severity, as there was no evidence that RDZ improved survival and other outcomes in these patients. Nevertheless, WHO continued to endorse including patients in trials with RDZ to establish with certainty whether RDZ had a positive effect on survival in mild to moderate, hospitalized COVID-19 patients. The Solidarity trial and its’ European sister trial, DisCoVeRy continued to randomize mild to moderate hospitalized COVID-19 patients to receive RDZ vs. standard of care until the 27th and 29th of January 2021, respectively. Inclusions into the RDZ arm were stopped due to futility in severe, but also mild to moderate, hospitalized COVID-19 patients. The results of the DisCoVeRy trial, with 857 inclusions, were recently published; no significant effect on viral kinetics, clinical progression or outcome was observed in RDZ treated patients compared to those treated with standard of care (42). In addition, EMA evaluated the full mortality and viral data from NIAID ACTT-1 data upon which EMA recommended to not start RDZ in COVID-19 patients already on mechanical ventilation and on ECMO. This guidance, that already considers RDZ as having a modest effect and small window of use, will be further updated when the final data from the DisCoVeRy and Solidarity trials are published. Nevertheless, a recent paper on the modelling of the antiviral efficacy of RDZ in COVID-19 hospitalized patients, based on nasopharyngeal normalized viral loads collected over the 29 days following randomization from 665 patients who participated in the DisCoVeRy trial, showed a 1-day reduction in time to SARS-CoV2 clearance compared to SoC (with large inter-individual variabilities). Results differ from the published results on viral kinetics from the DisCoVeRy trial, as analyses were stratified on time of treatment initiation, and on viral load at randomization, The impact was greater in patients with a high viral load at randomization (43). A recent meta-analysis of the 5 published RCTs on RDZ vs. control has also shown the modest effect of RDZ in hospitalized patients. Patients in the RDZ treatment group had a greater likelihood of hospital discharge, and clinical improvement was more rapid than the control group, yet no effect was observed on mortality (44). A recently published retrospective, multicenter study published by Gilead, based on the US Premier Healthcare inpatient database in which 28,855 RDZ-treated patients (within first 48-hours of hospitalization) were matched with 16,687 patients who did not receive RDZ during their hospitalization, showed a statistically significant reduction in mortality by day 14 and day 28 in the overall population and in most baseline oxygen subgroups,
except for those who needed high-flow oxygen at baseline (45). In a pragmatic, randomized, open-label, multicenter Canadian trial in hospitalized patients with COVID-19, comparing standard of care to RDZ plus standard of care, no significant effect on in-hospital mortality was observed (18.7% vs. 22.6%; RR 0.83 (95% CI 0.67 to 1.03)). However, there was significantly less need for mechanical ventilation in patients not mechanically ventilated at baseline in the RDZ plus standard of care arm compared to standard of care arm alone (8% vs. 15%; RR 0.53 (95% CI 0.38 to 0.75)) (46). Finally, in a nationwide population-based cohort study in Denmark, comparing death within 30 days of hospitalization and need of mechanical ventilation in two cohorts of patients hospitalized with COVID-19 from February to December 2020 (those who received RDZ + DXM to SoC alone (no RDZ + DXM)), showed that the 30-days mortality rate in the 1694 patients who received RDZ and dexamethasone was 12.6%, compared to 19.7% in the 1053 patients who received SoC alone (OR of 0.47 (95% CI: 0.38-0.57). A reduction of progression to mechanical ventilation was also observed (OR 0.36; 95% CI: 0.29-0.46). Nevertheless, the SoC cohort were patients hospitalized from February to May, 2020, and the RDZ plus dexamethasone cohort were patients hospitalized from June to December, 2020, suggesting the potential bias of time (47). The final results of the WHO SOLIDARITY trial have recently been published, showing a slight benefit in terms of halting disease progression and improving survival in patients treated with RDZ compared to SoC. A total of 14,304 patients participated in the trial from 35 different countries around the world. 11.9% of patients not ventilated initially, and who received RDZ, died, compared to 13.5% assigned to control (RR 0.86 [0.76–0.98], p=0.02) and 14.1% versus 15.7% progressed to ventilation (RR 0.88 [0.77–1.00], p=0.04) (48). A meta-analysis on individual patient data from the big randomized, controlled trials on RDZ is currently being performed.

At this stage, in vitro experiments do not suggest a modification of the antiviral activity of RDZ against BA.1 or BA.2 variants of concern (link) (4,49).

RDZ has been explored in different patient populations. A retrospective, monocentric, propensity score-matched observational study of RDZ in 31 patients with severe kidney disease, showed that when compared to a matched cohort of 31 patients that did not receive RDZ, there was no increase in adverse events (cardiological, neurological, kidney or liver), except for a significant increase in risk of hyperglycemic events. This risk was partially attributed to the increased use of dexamethasone in the RDZ treated cohort (50).

RDZ was also well tolerated (16% of serious adverse events), and recovery rates were high in 86 pregnant and post-partum women with severe COVID-19 (90% were discharged alive amongst the pregnant cohort, and 84% amongst the post-partum cohort), who received the drug via a compassionate use program (51). A review of RDZ in pregnant women with COVID-19 also concluded that there is a paucity of data on RDZ in this patient population. Nevertheless, RDZ appears to be well tolerated in the second and third trimesters of pregnancy, with a low risk of serious adverse events. No conclusions could be made concerning the administration of RDZ to patients during the first trimester of pregnancy, due to the paucity of data (52).

Available evidence in the ambulatory setting:

Although RDZ place in the therapeutic arsenal against COVID-19 remains controversial, on December 16, 2021, EMA adopted a positive opinion recommending RDZ in COVID-19 patients not requiring supplemental oxygen and are at increased risk of progressing to severe COVID-19.

In a randomized, double-blind, placebo-controlled, multi-centre clinical trial evaluating treatment with RDZ in an outpatient setting, 562 unvaccinated adult patients with confirmed COVID-19 and at least 1 risk factor for
disease progression, were randomized 1:1 to IV remdesivir (200mg on d1, 100mg on d2 and d3) or placebo plus SoC. **Patients with renal insufficiency were not excluded from the trial except if they weighed < 48 Kgs.** Stratification was done by residence in a skilled nursing facility (yes/no), age (<60 vs ≥60) and region (US vs ex-US). Median (Q1, Q3) duration of symptoms prior to treatment was 5 (3,6) days; median viral load was 6.3 log10 copies/mL at baseline. The study was terminated early for administrative reasons, and less than half of the planned original enrollment was achieved. The primary endpoint was the proportion of patients with COVID-19 related hospitalisation or all-cause 28-day mortality. Events occurred in 2 (0.7%) patients treated with remdesivir compared to 15 (5.3%) patients concurrently randomized to placebo, demonstrating an 87% reduction in COVID-19-related hospitalisation or all-cause mortality compared to placebo (hazard ratio, 0.134 [95% CI, 0.031 to 0.586]; p=0.0076). No deaths were observed at Day 28 in either group (53). These results support the use of antiviral treatments very early on in the course of COVID-19 infection, and open the discussion concerning the possibility of administering a short-course (3-days) RDZ treatment to patients with chronic renal insufficiency. 18 patients with mild to moderate chronic renal disease participated in the PINETREE trial.

### 2.2. IMMUNOMODULATORY AGENTS, ANTI-INTERLEUKIN THERAPY

**Main message:** Immunomodulatory agents are a varied group of drugs that may prevent or dampen hyper-inflammatory responses which are associated with clinical deterioration and mortality among COVID-19 patients (54,55). Potential adverse events, immunosuppression and drug interactions need to be carefully taken into consideration when choosing to treat patients.

**Available evidence in the hospital setting:** Several interleukin (IL) and complement blockers used in inflammatory diseases such as giant cell vasculitis or rheumatoid arthritis have been proposed for repurposing based on limited clinical experience and small observational studies. These drugs include tocilizumab (IL-6-receptor antagonist) (56,57), sarilumab (IL-6 receptor antagonist), siltuximab (anti-IL-6) and anakinra (IL-1-receptor antagonist), as well as complement inhibitors such as C3 and C5 inhibitors, C5a receptor inhibitors and C1 esterase inhibitors. Eight randomized trials assessing the use of tocilizumab (TCZ) in hospitalized COVID-19 patients have been recently published (58–60). These trials were highly heterogeneous regarding the severity of the patients included.

Recently, a WHO-initiated meta-analysis on 27 randomized trials has been published, showing that IL-6 antagonist was associated with lower 28-day all-cause mortality in patients hospitalized for COVID-19 (61). Importantly, a significant mortality benefit was only found when IL-6 receptor antagonists were co-administered with glucocorticoids, and most evident among patients who received respiratory support with oxygen by nasal cannula, face mask, high-flow nasal oxygen or non-invasive ventilation versus those who required invasive mechanical ventilation (61,62). There was not a clear benefit associated with anti-IL-6 among patients who already required mechanical ventilation at the time of randomization. Data were strongest for tocilizumab as compared to sarilumab (less available evidence). The accompanying editorial however points out some limitations to this meta-analysis, the most important being the lack of accounting for the baseline risk of death (62). This might explain the finding that COV-AID, a study carried out in a Belgian setting, showed no added benefit from anti-IL-6 treatment (63).

Most international guidelines, including those of the European Respiratory Society (ERS), the National Institutes of Health (NIH), and the Infectious Diseases Society of America (IDSA) have now formulated a conditional recommendation, with moderate certainty of evidence, towards the addition of tocilizumab to
standard of care (i.e. steroids) rather than standard of care alone, in hospitalized adults with progressive severe (SpO2 ≤94% on room air, including patients on supplemental oxygen) or critical (mechanical ventilation and ECMO) COVID-19 who have elevated markers of systemic inflammation (64). In the largest trial on treatment with tocilizumab, the criterion for systemic inflammation was defined as CRP >75 mg/L. Both RECOVERY and REMAP-CAP (the two tocilizumab trials that reported a benefit) initiated treatment early (randomization at median of two days of hospitalization in RECOVERY; <24 hours in the ICU for REMAP-CAP), suggesting tocilizumab may be more beneficial in people with early, rapidly progressive disease. The recommended dosage of tocilizumab is 8mg/kg IV with a maximum dose of 800mg.

The product RoActemra (tocilizumab) was approved on the 17th of December, 2021 for treatment of hospitalised adult patients with severe COVID-19 who are already receiving treatment with corticosteroids and require extra oxygen or mechanical ventilation (link). However, it must be mentioned that there are currently significant drug shortages of this drug, and there are patients who depend on this drug for other indications than COVID-19. It is in this light that the drug must be prioritized. It is recommended to give priority to patients to receive this drug in the following order: patients with cytokine release syndrome caused by chimeric antigen receptors T-cell medicines, giant cell arteritis, systemic juvenile idiopathic arthritis, juvenile idiopathic polyarthritis, and severe rheumatoid arthritis). Furthermore, it is important to note that there is currently no reimbursement for administration of tocilizumab in COVID-19 patients in Belgium.

A recent double-blinded, RCT study in 1060 patients hospitalized for COVID-19, included across 37 sites in Italy and Greece, also showed a clear outcome benefit in patients with a concentration of soluble urokinase plasminogen activator receptor (suPAR) ≥ 6ng/mL who received anakinra (100 mg QD sub-cutaneously for 7-10 days) compared to those who received standard of care + placebo. 50.4% (204/405) of patients receiving anakinra had fully recovered with no viral RNA detected on day 28 compared to 26.5% (50/189) of patients receiving placebo, and 3.2% (13/405) and 6.9% (13/189) of patients in the anakinra and placebo arms, respectively, died. Therefore, the unadjusted proportional odds of having a worse score on the 11-point WHO-CPS at day 28 with anakinra was 0.36 versus placebo (95% confidence interval (CI) 0.26–0.49, P < 0.0001. Because suPAR measurement is not widely available in the routine laboratory setting, the authors performed a post-hoc analysis to identify other tools to identify patients who might benefit from anakinra treatment. They found that predictors of favorable responses to anakinra are a combination of at least two measures of CRP >50 mg/L, neutrophil-to-lymphocyte ratio (NLR) >5.5, ferritin >700 ng/ml and aspartate aminotransferase (AST) > 44 U/L (65). Nevertheless, this prediction score remains to be validated in a prospective study.

Kineret (anakinra) has also just been approved on the 16th of December, 2021 for treatment of COVID-19 in adult hospitalized patients with pneumonia who are at risk of developing severe respiratory failure, and who have a measured plasma concentration of suPAR ≥ 6ng/ml (link). Currently, the measurement of suPAR cannot be carried out in a routine fashion in Belgian laboratories.

**Notes on treatment with immunomodulatory agents:** Caution must be exercised when used in patients with active concomitant (myco-) bacterial and fungal infections and in chronically immunosuppressed patients. Alternative inflammatory markers instead of CRP (such as procalcitonin) may be used to monitor infectious complications in patients treated with IL-6-blockers.

**Available evidence in the ambulatory setting:** No data.
2.3. MONOCLONAL ANTIBODIES

Main message: Treatment with monoclonal antibodies (mAbs) has consistently demonstrated clinical benefit (reduction of hospital admissions and deaths) provided they are administered within 7-10 days after symptom onset to COVID-19 (out)patients at risk for severe disease progression. A set of criteria and conditions were elaborated in a previous version of the guideline to define patients eligible for this treatment. Since the emergence of VOC (in particular, the Omicron variant), a number of mAbs have shown an in-vitro decrease in their neutralisation capacity. It is essential to regularly consult the monitoring data concerning the circulating VOC. Furthermore, it is important to stress that very early administration of this treatment is essential, even if this might be challenging to organize because it requires appropriate hospital infrastructure and excellent collaboration with primary care for timely appropriate referral.

To help clinicians with the difficult selection of patients for whom this intervention would be most beneficial, the working group considers that immunosuppressed patients should get the highest priority for the moment (including patients with end-stage kidney or liver disease). For all other eligible patients, two (quite similar) scoring systems in use in the US (Mayo Clinic (66) and Utah (link) are provided here below (Annex 5.4); they give some weighted ponderations to the risk factors for adverse outcome. Even if these scores are not entirely evidence-based and have only been internally validated, the working group suggests prioritizing mAb administration to those (out)patients with the highest scores, that reflect in fact cumulative co-morbidities. No rigid cut-off can be however provided for the time being. The cut-off to be used will depend upon availability of mABs. Of note, mAbs could also be considered as salvage therapy among (hospitalized) patients with persistent viral shedding due to an immunocompromised condition, although this very situation has been poorly studied so far (67). Careful monitoring of the viral evolution would be key here.

- A summary for all monoclonal antibodies is available below (link).
- An overview of individual study results is provided in chapter 3 (Table 2).
- Please consult the algorithm in Annex 5.3 to assess whether a patient is eligible for treatment with monoclonal antibodies.
- Please consult the scoring system in Annex 5.4 to assess how to prioritize mABs, when availability is limited.

Sotrovimab was authorized for marketing on the 16th of December 2021. It is no longer recommended in Belgium since the emergence of Omicron subvariants (Omicron BA.2 and currently BA.4 and BA.5).

Resistance of SARS-CoV-2 variants to mAbs and the changing epidemiology must be considered before starting treatment.

Information on genomic SARS-CoV-2 surveillance in Belgium is available via the National Reference Laboratory¹ and Sciensano’s weekly epidemiological report.²

¹ Genomic Surveillance of SARS-CoV-2 in Belgium
² COVID-19 Weekly Epidemiological Report, chapter 3.4 Molecular surveillance:
Available evidence: Dozens of monoclonal antibodies (mAbs) targeting the Receptor Binding Domain (RBD) of the spike protein (S protein) (with the exception of sotrovimab which does not directly block the ACE2 receptor) have been developed and more than 50 trials are being conducted (68). Mutations in the spike protein of SARS-CoV-2 variants may impact the expected clinical efficacy of monoclonal antibody therapies.

Given the long half-life, a single injection (mostly intravenous, occasionally subcutaneous or intramuscularly) is generally used (69).

A summary followed by an overview per molecule is provided below.

2.3.0. Summary
mAbs can be considered on a case-by-case basis for COVID-19 patients with mild to moderate disease at high risk of clinical deterioration, on the condition that these therapeutics are administered early after infection onset.

Intrinsic resistance to monoclonal antibodies should also be considered, particularly in light of the successive emergence of variants. Currently, in the context of BA.5 dominance, the utilization of Sotrovimab should be discouraged unless evidence of an infection with another variant can be demonstrated. Evusheld® (tixagevimab co-packaged with cilgavimab), retains in vitro reduced activity against BA.5 (reduced activity of cilgavimab, and no activity of tixagevimab) (3). These mAbs have been less studied for treatment in immunocompromised patients (a group for whom such treatments appear attractive), in vaccinated individuals or persistent shedders. Furthermore, efficacy studies against new emerging SARS-CoV-2 variants are necessary to understand whether these treatments will remain effective as the genomic landscape evolves.

2.3.1. Bamlanivimab
Available evidence in the hospital setting: A phase II RCT with bamlanivimab (trial conducted by the ACTIV-3/TICO LY-CoV555 Study Group) in hospitalized patients, bamlanivimab (co-administered with remdesivir) did not demonstrate any clinical benefit (70).

Available evidence in the ambulatory setting: A phase II RCT with bamlanivimab (BLAZE-1, NCT04427501) in mild and moderate COVID-19 outpatients showed promising results on viral decline, symptom resolution and hospitalization (71). Several US real world case-control studies have shown that bamlanivimab treatment prevents hospitalization among mild to moderate COVID-19 infections. However, these studies were performed between November 2020 and February 2021, when few bamlanivimab resistant variants of concern (VOC) were in circulation (72,73). Currently, due to the circulation of the delta and Omicron variants, the prescription of this mAbs is no longer recommended.

2.3.2. Bamlanivimab + etesevimab
Available evidence in the hospital setting: No data.

Available evidence in the ambulatory setting: The phase 2/3 portion of BLAZE-1 outpatients treated with the combination of bamlanivimab and etesevimab, administered together in a single infusion, showed a significant
reduction in viral load on day 11, while no significant change was seen on viral load with bamlanivimab alone. Among secondary endpoints, there were no consistent differences between the monotherapy and the combination therapy versus placebo for the other measures of viral load or clinical symptom scores (74). In the RCT, phase 3, BLAZE-1 trial, including 1035 outpatients with mild or moderate COVID-19, at high risk for progressing to severe COVID-19 (including 6.4% of immunosuppressed patients) 2.1% patients in the bamlanivimab 2800 mg + etesevimab 2800 mg group had a hospitalization or died by Day 29 versus 7.0% in the placebo group (relative risk difference, 70%; P<0.001, NNT=20.4) (75). No deaths occurred in the bamlanivimab–etesevimab group compared to 10 deaths in the placebo group. According to the unpublished results of the BLAZE-4 phase 2 trial, the only authorized dose of bamlanivimab is 700 mg combined with etesevimab 1400 mg (link). In the US, on June 25, 2021, the distribution of bamlanivimab plus etesevimab was temporarily paused as virologically resistant variants Gamma (P.1) and Beta (B.1.351) constituted >5% of samples identified through genomic surveillance (link). On the 2nd of November 2021, EMA ended the rolling review of bamlanivimab and etesevimab after Eli Lilly decided to withdraw from the process.

Preliminary data on Omicron variant indicate that it escapes neutralization by bamlanivimab+etesevimab (3).

2.3.3. Casirivimab + imdevimab (Ronapreve, REGN-COV)

Ronapreve® (REGN-COV, REGN-CoV2 or REGN-CoV2) consists of two antibodies that bind to different regions of the SARS-CoV-2 spike protein receptor. This cocktail of mAbs is no longer available in Belgium and is not recommended for Omicron variants.

Available evidence in the hospital setting:

Treatment of hospitalized patients with severe COVID-19:

In the RECOVERY, RCT, open-label trial, REGN-COV (casirivimab 4g and imdevimab 4g, IV) plus standard of care (including corticosteroids) was compared with standard of care alone, in hospitalized COVID-19 patients. 3153 patients (32%) were seronegative for SARS-CoV-2, 5272 (54%) seropositive and 1360 (14%) with unknown status at baseline. In the seronegative group, 396 (24%) in the REGN-COV group and 451 (30%) of standard of care died within 28 days (rate ratio 0.79 95% CI 0.69-0.91; p=0.0009 NNT: 16.7). The proportional effect of REGN-COV on mortality differed significantly between seropositive and seronegative patients (p-value for heterogeneity = 0.001). The authors conclude that REGN-COV, in hospitalized patients with severe COVID-19, should only be used in SARS-CoV-2 seronegative patients. This is the first study to have shown efficacy of mAbs in hospitalized patients with COVID-19 (76).

Available evidence in the ambulatory setting:

Treatment of mild or moderate COVID-19 outpatients:

In an interim analysis of a phase 2-3 trial studying the effect of a combination regimen of casirivimab and imdevimab (NCT04425629) in 275 outpatients, a significant decline in viral load on day 7 was observed when compared to placebo, especially in seronegative patients and in patients with high viral load (77). However, the impact on clinical outcomes (medically attended visit) were less clear.

In the phase 3 portion of this same study in high-risk outpatients who received various doses of REGN-COV (2400mg vs 1200mg vs placebo), the results showed that both REGN-COV dosage regimens significantly reduced hospitalization or death by day 29 (respectively 71.3% reduction; p<0.001[18/1355, 1.3% vs 62/1341, 4.6%, NNT 30.3], and 70.4%; p=0.002 [7/736, 1.0% vs 24/748, 3.2%, NNT=45.45]) [48]. Efficacy of REGN-COV...
(hospitalization or death, resolution of symptoms and viral load reduction) was consistent across subgroups, including patients that were SARS-CoV-2 seropositive at baseline. Based on that study, (78), the FDA modified the dosage to casirivimab 600mg plus imdevimab 600mg (June 2021). The same dosage is approved by the MHRA (The UK Medicines and Healthcare products Regulatory Agency and since the 12th of November by the EMA [link]. Subcutaneous injection can be given when IV administration is not feasible or would lead to treatment delay (link).

Post-exposure prophylaxis:
The results of a phase 3 trial (part A) on subcutaneous REGEN-COV prophylaxis among uninfected (PCR negative) household contacts exposed to SARS-CoV-2 at home showed 81.4% risk reduction of a symptomatic infection compared with placebo (11/753 [1.5%] vs. 59/752 [7.8%], number needed to treat [NNT]: 15.9) and a shorter time to resolution of symptoms (1.2 vs. 3.2 weeks). One third of the subjects (30.5%) had at least one risk factor for severe COVID-19. The main risk factors included: BMI ≥ 35 kg/m2 (13.7%), age ≥ 65 years (8.7%), and diabetes (6.8%). Very few immunosuppressed patients were included in the study (1.5%) (79).

In Part B of the same study, which compared REGEN-COV SC to placebo for preventing the progression of early SARS-CoV-2 infection in asymptomatic close contacts (PCR SARS-CoV-2 positive, primary analysis focused on seronegative participants), a 31.5% relative risk reduction of developing symptomatic infection in the REGN-COV group (29/100 [29.0%] vs 44/104 [42.3%]; p=0.038), was observed (80).

The eight-month post hoc analysis of the part A study shows that a single SC administration of casirivimab + imdevimab prevents symptomatic infections up to 5 months after injection. Patients could be vaccinated after the first 28 days of follow-up and the numbers of vaccinated patients were balanced in both groups (about 35%). It should be noted that the study started on 13 July 2020 and ended on 4 October 2021, before the emergence of the Omicron lineage variants (Delta period). Therefore, the results of this study cannot be transposed to the current epidemiological situation, for which the use of Ronapreve is contraindicated (81).

On the 12th of November 2021, the EMA gave a marketing authorisation for Ronapreve (casirivimab / imdevimab) to prevent and treat COVID-19 (within 7 days of symptom onset) in adults and adolescents as of age 12, ≥40 kg, who do not require supplemental oxygen and are at increased risk for progressing to severe COVID-19. The dosage regimen for treatment and post-exposure prophylaxis is a single 600+600mg iv infusion or sc injection. For pre-exposure prophylaxis, dosage regimen is initially a 600+600mg infusion/injection followed by 300+300mg infusion/injection every 4 weeks (no data on repeat dosing beyond 24w). This mAbs cocktail is no longer recommended in Belgium due to the current epidemiology (Omicron variants).

2.3.4. Regdanvimab
Available evidence in the hospital setting: No data.
Available evidence in the ambulatory setting:

A phase 2-3 trial of 325 adult outpatients with COVID-19 (study CT-P59, unpublished) showed a smaller proportion of severe COVID-19 (hospitalization, oxygen requirement or death) by day 28 of 4.4% when analysing pooled dosage regimens of CT-P59 (40mg/kg and 80mg/kg) versus 8.7% in the placebo group (link).

A main study involving 1,315 patients with COVID-19 showed that Regkirona led to fewer patients requiring hospitalisation or oxygen therapy, or death, when compared with placebo. Among the patients at increased risk of developing severe illness, 3.1% of patients treated with Regkirona (14 out 446) were hospitalised,
required supplemental oxygen or died within 28 days of treatment compared with 11.1% of patients on placebo (48 out of 434). The majority of patients in the study were infected with the original SARS-CoV-2 virus or the Alpha variant; data on the efficacy of Regkirona against new circulating SARS-CoV-2 variants is currently limited.

On the 12th of November 2021, EMA gave a marketing authorisation for Regkirona (regdanvimab, CT-P59) for treating adult patients with COVID-19 who do not require supplemental oxygen and are at increased risk for progression to severe COVID-19. The posology is one single iv infusion 40mg/kg.

A present, there is no availability of this product in Belgium and it is no longer recommended due to the current epidemiology (Omicron variants).

2.3.5. Sotrovimab
Available evidence in the hospital setting:

In a multinational, randomised, placebo-controlled clinical trial (NCT04501978), 546 hospitalised COVID-19 patients with symptom onset of up to 12 days received either sotrovimab 500 mg IV (n=184), or BRII-196 1000 mg plus BRII-198 1000 mg IV - Brii Biosciences (n=183) or placebo (n=179), in addition to standard care (including remdesivir). Patients were excluded if they required high flow oxygen therapy. The enrolment was halted on the basis of the interim futility analysis. Neither sotrovimab or BRII-196 plus BRII-198 showed efficacy for improving clinical outcomes (ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group) (82).

Available evidence in the ambulatory setting:

The phase 3 COMET-ICE trial (NCT04545060), evaluating a single 500 mg infusion of sotrovimab compared to placebo in 1057 high-risk outpatients (most common risk factors: obesity: 63%, >55 years: 46% and diabetes: 23%) demonstrated an 79 % (p < 0.001) reduction in hospitalization or death at day 29 in the sotrovimab group vs. placebo (1% vs 6% NNT:20) (83).

On the 16th of December 2021, the EMA issued a positive opinion on Xevudy®, thus resulting in a grant for marketing authorization for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age of weighing at least 40 kg) (link). Currently, in the context of BA.5 dominance the administration of Sotrovimab should be discouraged unless evidence for an infection with another variant can be demonstrated.

2.4.7 Tixagevimab and cilgavimab (AZD7442)

AZD7442 is a combination of two fully human, long-acting SARS-CoV-2-neutralizing antibodies, AZD8895 (tixagevimab) and AZD1061 (cilgavimab). The half-life extension more than triples the durability of its action compared to conventional mAbs (84).

Available evidence in the hospital setting:
The AZD7442 combination is currently being evaluated in the hospitalized patients with COVID-19 in the ACTIV-3 trial (NCT04501978) and the DisCoVeRy trial (NCT04315948).

Available evidence in the ambulatory setting:

In the ongoing phase III PROVENT pre-exposure prophylaxis trial (NCT04625725), 5197 unvaccinated, SARS-CoV-2-negative adult patients who were expected to have an inadequate response to vaccination (but <4% of immunocompromised included) or an increased risk of exposure, were randomized to receive intramuscular AZD7442 (150 mg tixagevimab +150 mg cilgavimab, 3460 patients) or placebo (1737 patients). The study period was between November 2020 and March 2021. The primary efficacy end point was symptomatic COVID-19 at day 183 and occurred in 8/3441 (0.2%) in the AZD7442 group and 17/1731 participants (1.0%) in the placebo group (relative risk reduction, 76.7%; 95% CI, 46.0 to 90.0; P<0.001). Five critical COVID-19 cases and 2 deaths occurred in the placebo group. One death due to myocardial infarction occurred in the AZD7442 group (<0.1%), and thus requires vigilance in patients with cardiovascular disease (85).

The TACKLE study is an ongoing phase 3 RCT including 910 non-hospitalised, unvaccinated patients with mild to moderate COVID-19 (456 in the tixagevimab-cilgavimab 600mg IM and 454 in the placebo group). The mean age of the participants was 46.1 years. Only 5% were immunocompromised. At Day 29, 18/407 (4%) of patients in the tixagevimab-cilgavimab group versus 37/415 (9%) of 415 in the placebo group progressed to severe disease or death (relative risk reduction 50.5% [95% CI 14.6-71.3]; p=0.0096, NNT=20). Three COVID-19-related deaths occurred in the tixagevimab-cilgavimab group, and six in the placebo group. There was no difference in adverse events between the 2 groups. Note that this study was conducted before the Omicron era (86).

The EMA started the rolling review of Evusheld® (tixagevimab and cilgavimab) on 14 October 2021. On the 24th of March 2022, EMA recommended granting a marketing authorization for Evusheld for the prevention of COVID-19 in adults and adolescents from 12 years of age, weighing at least 40kg before potential exposure to the SARS-CoV-2 virus (link).

The dosage of EVUSHELD® is 150 mg of tixagevimab and 150 mg of cilgavimab administered as two separate consecutive intramuscular injections. In the US and UK, the dosage has been increased to 300mg tixagevimab/300mg cilgavimab, due the VOC Omicron BA1.

A higher proportion of subjects receiving EVUSHELD® had serious adverse events of myocardial infarction and heart failure. All subjects had cardiac risk factors and/or a history of cardiovascular disease, and there was no clear temporal pattern (link).

The BA.2, BA. 4 and BA. 5 Omicron variant were not yet circulating during the period of the initial tixagevimab+ cilgavimab clinical trials.

Up to now, no RCT studies on treatment with mAbs in vaccinated individuals have been published. Although vaccination prevents severe disease and mortality in a large majority of patients, breakthrough infections have been reported (link). The final decision on mAbs treatment should integrate the clinical opinion of the prescribing (hospital-based) physician and a multidisciplinary expert panel, consisting of at least an infectious disease physician.
Viral genomic monitoring during mAbs therapy is suggested to monitor the risk of developing resistance during treatment. Patients treated with mAbs should be under quarantine and a SARS-CoV-2 nasopharyngeal PCR test should be performed 7-10 days after treatment. If the test is positive, virus sequencing should be performed. SARS-CoV-2 variant classifications and definitions are available via the CDC. Monoclonal antibodies bind to epitopes on the spike protein, which is used as an immunogen in all COVID-19 vaccines. Therefore, it is possible they may interfere with the development of an effective immune response to COVID-19 vaccines. Based on the estimated half-life of mAbs and evidence suggesting that reinfection is uncommon within the 90 days after initial infection, the CDC recommends deferring vaccination for at least 90 days after receiving mAbs (link).

2.4. CONVALESCENT PLASMA

Main message: Current high-quality evidence does not demonstrate that convalescent plasma (CPP) improved clinical outcomes among hospitalized patients with COVID-19 disease. There is currently insufficient evidence on the early administration of convalescent plasma to prevent severe disease among high-risk patients.

Available evidence in the hospital setting: Animal studies with SARS-CoV-1 and SARS-CoV-2 infections indicate a protective role of neutralizing antibodies. In addition to marked antiviral activity, plasma administration has been associated with decreased inflammatory markers in a trial in India (87). Several observational studies, non-controlled and controlled non-randomized trials, RCT’s, and several meta-analyses and living reviews have been published (88)(89). Several observational studies show survival benefit of transfusing COVID-19 convalescent plasma (CPP) with high antibody titers (90). In contrast, RCT’s could not demonstrate a benefit on mortality of CPP in hospitalized patients with COVID-19, among which the RECOVERY trial is the largest one published until now (91)(92)(93)(94)(95)(96)(97). The RECOVERY trial randomized 11,558 patients to convalescent plasma or usual care. They did not find any difference in 28-day mortality between the two groups (both 24%). There was also no difference in secondary outcomes such as discharge at day 28 or progression to mechanical ventilation or death in those not mechanically ventilated at randomization (98). The REMAP-CAP study, carried out in critically ill patients also halted recruitment in the convalescent arm due to futility (99). A Cochrane review including some unpublished data (including those from the RECOVERY trial at that time), and a meta-analysis performed by the RECOVERY group, did not find a difference in mortality between convalescent plasma and usual care (89,98)(100–103)(104)(105).

Notes on treatment with convalescent plasma: The CONFIDENT study has been terminated and its results were presented at the SIZ congress (June 15th, 2022); 28 day mortality was 35.4% in patients receiving convalescent plasma (with high titers of neutralizing antibodies) as compared to 44.7% in control patients (p=0.043). The full manuscript is currently under peer review. At this moment there are no clinical trials in Belgium on early administration of COVID-19 convalescent plasma in risk groups. Both Rode Kruis and Croix Rouge are collecting plasma from patients who have experienced COVID-19. Whenever possible, patients should be informed at discharge on the possibility to donate plasma and to contact their local RKV/CR center. The AFMPS/FAGG has recommended that donation should only take place more than 28 days after symptoms have ended. Of note, administration of CCP could be considered in case of persistent viral shedding (> 1 month) in severe COVID-19 patients with B cell-related immunosuppression (including patients on Rituximab and other B-cell depleting agents) unable to mount an antibody response, as shown in several case reports, case...
series and a retrospective case-control study (106) (107) (108). The volume and antibody titer used in different reports varies (109) (110).

A MEURI (Monitored Emergency Use of Unregistered Investigational Interventions) protocol, similar to the Urgent Medical Need program of the FAGG/AFMPS/AFMHP was established by RKV/CR to obtain CCP for these very restricted situations where inclusion in the current clinical trials (CONFIDENT-plasma) is not possible. CCP is a standard fresh frozen plasma from convalescent voluntary donors with SARS-CoV-2 neutralizing antibodies and conforms to all legal criteria. Criteria for this MEURI delivery, including the requirement for registration of clinical data, are defined and available via your hospital’s blood bank laboratory or RKV/CR. Of note, emergence of viral populations with significant mutations in the spike protein has been reported during treatment of immunocompromised patients with convalescent plasma (111). Furthermore, the genomic differences between SARS-CoV-2 variants globally and regionally affect response to convalescent plasma treatment. Reduced in vitro neutralization to the current Omicron variant has been shown after convalescence from previously circulating SARS-Cov2 variants (112). Formal studies evaluating the value of convalescent plasma in this setting are needed (113,114).

Available evidence in the ambulatory setting: An Argentinian blinded RCT evaluated early (i.e. within 3d of symptom onset) administration of convalescent plasma in older COVID-19 patients, i.e. >75y or >64 -75y with comorbidities (115). They found a RR reduction of 0.52 (95% CI 0.29-0.94). The study was terminated early due to a fall in the COVID-19 incidence in Argentina, including 76% percent of the previewed inclusion number. On the other hand, the NIH trial C3PO evaluating convalescent plasma compared to standard of care for treatment of early-onset (<7 days), non-hospitalized COVID-19 patients (≥50 years old or with a risk factor) was halted after interim analysis of 511 participants (of the 900 planned) found no difference in disease progression between the two groups (116). The same results were found in pooled data from the ConV-ert, (Spain), and CoV-Early (The Netherlands), double blind randomized placebo-controlled trials in ambulatory COVID19 patients (n= 797, ≥ 50y with symptom onset ≤ 7d) (117). Sullivan et al, on the other hand, included 1225 patients in a double-blind placebo (plasma) controlled randomized trial, and found an absolute risk reduction for hospitalization within 28d of 3.4% (2.9% in CPP treated vs 6.3% in plasma treated) (118). The differences found between previous studies might have several explanations: patient population included, time of plasma infusion, type of placebo,... It is important to note that most studies were run before the current omicron variant and high vaccination uptake, and the group of immunocompromised patients who might benefit from CPP was underrepresented in the currently published studies. More results from RCT’s evaluating early administration of CPP in vulnerable groups are still expected (COVIC-19 NCT 05271929).

2.5. INTRAVENOUS IMMUNOGLOBULINES

Main message: At this moment there is no place of IVIG or hIVIG for severe COVID 19. For its place in the treatment of COVID complications, like multisystem inflammatory syndrome, we refer to current international guidelines.

Available evidence in the hospital setting:
Early in the pandemic, several small trails reviewed in a meta-analysis, showed promising results of IVIG treatment in severe COVID, low level of certainty (119). Recently, an additional double-blind, placebo-controlled, RCT in patients with COVID 19 ARDS could not find an effect on ventilator free days at 28d. This study had several limitations; particularly, the study was probably underpowered due to the small effect measured (120).
Studies on hyperimmune/concentrated immunoglobulin preparations are scarce, a pilot phase I/II study in severe COVID showed that it was safe and a non-significant positive effect on survival (121). A more recent, international, multi-centric, double-blind, placebo-controlled, phase 3, randomised trial in 593 hospitalized patients also failed to show efficacy on day 7 (based on a 7-category ordinal endpoint) (122).

Available evidence in the ambulatory setting: No data.

2.6. JANUS KINASE INHIBITORS

Main message: Baricitinib (and other Janus kinase inhibitors) are promising anti-inflammatory drugs targeting multiple cytokines that have shown a survival benefit when administered in addition to standard of care (i.e. systemic corticosteroids). The EMA is currently reviewing baricitinib as a possible COVID-19 treatment. NIH recommends baricitinib in addition to dexamethasone in severe patients as an alternative to tocilizumab. Tofacitinib is also proposed as an alternative to baricitinib when unavailable (link).

2.6.0. Baricitinib

Available evidence in the hospital setting: Baricitinib is an orally administered, selective inhibitor of Janus kinase (JAK) 1 and 2. In a randomized placebo-controlled trial in patients with moderate and severe COVID-19, treatment with baricitinib 4mg qd and remdesivir was shown to reduce recovery time and to accelerate improvement in clinical status when compared to RDZ alone (123). Corticosteroids were not considered standard of care in this study, so the comparison of baricitinib versus baricitinib in association with corticoids was not evaluated. Prices of baricitinib and RDZ are significantly higher than steroids, so this treatment should not be used as standard of care pending further evaluation: including use without RDZ, use on top of steroids or use in comparison with steroids. One large double blind randomized placebo-controlled trial (SOC included systemic corticosteroids in 80% of patients) showed no influence of baricitinib on combined primary endpoints (progression to requiring high-flow oxygen, non-invasive ventilation, invasive mechanical ventilation or death by day 28), but there was a significant reduction of mortality at day 28 (hazard ratio [HR] 0.57 [95% CI 0.41–0.78]; nominal p=0.0018) and day 60 (HR 0.62 [95% CI 0.47–0.83]; p=0.0050) (124). In an addendum cohort of critically ill patients (baseline IMV/ECM, with 86% corticosteroid treated), the COV-BARRIER study demonstrated a reduction in 28-day all-cause mortality compared to placebo (39.2% vs 58.0%; hazard ratio [HR]=0.54 [95%CI 0.31–0.96]; p=0.030). This reduction persisted through day 60 (mortality 45.1% vs 62.0%; HR=0.56 [95%CI 0.33–0.97]; p=0.027) (125). Preliminary results (pre-print) of the baricitinib arm in the RECOVER trial have recently become available (126). Recently, a COCHRANE meta-analysis included those four trials (10815 participants), together with one trial of tofacitinib (289 participants) and one trial of ruxolitinib (41 participants). It showed that JAK inhibitors probably decrease all-cause mortality at up to day 28 (95/1000 participants in the intervention group versus 131/1000 participants in the control group; 6 studies, 11,145 participants; risk ratio (RR) 0.72, 95% confidence interval (CI) 0.57 to 0.91; moderate-certainty evidence), and decreased all-cause mortality at up to day 60 (125/1000 participants versus 181/1000 participants; RR 0.69, 95% CI 0.56 to 0.86; 2 studies, 1626 participants; high-certainty evidence) (127).

On the 29th of April, the EMA began the evaluation of an application to extend the use of Olumiant (baricitinib) to include treatment of COVID-19 in hospitalized patients from 10 years of age who require supplemental oxygen. The living WHO guideline has just given a strong recommendation to administer baricitinib as an alternative to IL-6 receptor blockers in combination with corticosteroids to patients with severe or critical COVID-19 (128).
2.6.1. Tofacitinib

**Available evidence in the hospital setting:** Tofacitinib is an oral JAK-inhibitor approved for the treatment of rheumatologic diseases and ulcerative colitis (Xeljanz®). A RCT evaluated the effects of tofacitinib (10 mg q12h for up to 14 days) in hospitalized COVID-19 patients not requiring ventilation (within 72 hours of admission) in comparison to placebo. This treatment led to a significant reduction in the incidence of death or respiratory failure (18.1% vs 29.0%, risk ratio 0.63, \( P=0.04 \)); this effect was consistent across the different levels of oxygen requirements at baseline. One limitation of the study is its relatively limited sample size (n=289); also, corticosteroid use was high in both groups (78.5%), while other immunomodulatory treatments were not allowed. The study showed no increased risk of secondary infections associated with the use of tofacitinib. Importantly, patients with a history of or current thrombosis, personal or first-degree family history of blood clotting disorders, immunosuppression, any active cancer, or those with some cytopenias were excluded from this trial. A reduced dose of 5mg twice daily was administered in patients with reduced glomerular filtration rate (<50mL/minute), in those with moderate liver dysfunction and in those with a strong CYP3A4 inhibitor or a combination of a moderate CYP3A4 inhibitor and a strong CYP2C19 inhibitor (129). Nevertheless, the WHO living guideline has given a weak recommendation against its use in patients with severe or critical COVID-19, outside of clinical trials due to low certainty of evidence (128).

**Available evidence in the ambulatory setting:** No data.

2.6.2. Ruxolitinib

Only preliminary data are available for ruxolitinib; the data is not sufficient to support its use outside of studies (130).

2.7. INTERFERON

**Main message:** Interferons (IFN) have antiviral effects and modulate the immune response (131). At this moment there is insufficient evidence to support the use of interferon treatment in early or severe COVID-19 disease.

**Available evidence in the hospital setting:** There are several case series, case-control trials, small RCT’s and the interim results of the WHO-solidarity trial that have been published so far. Hung et al compared combination therapy including IFN β-1b, ribavirin and lopinavir/ritonavir (n=86) vs lopinavir/ritonavir alone (n= 41) in an open label RCT (132). Only 52 patients starting therapy <7d of symptom onset received at least one dose of interferon, as by study protocol. They found a shortened viral shedding and faster clinical improvement in the IFN-containing arm. Another RCT evaluated IFN β-1b with or without standard of care including hydroxychloroquine plus lopinavir/ritonavir or atazanavir/ritonavir (both groups n=33). They found a faster clinical improvement, in primary outcome; and a decreased ICU admission, although the study was probably underpowered for this (133). The same group also evaluated IFN β-1a in addition to the same standard of care (n=42) vs standard of care alone (n=39), and could not find any difference in clinical response.
Decreased mortality was found in the IFN group. This study has several limitations: >30% of patients had no laboratory-confirmed infection, a very high mortality was observed in the control group and a large drop-out was seen in each study group. Furthermore, IFN therapy was associated with more adverse events. Results from the WHO-SOLIDARITY trial show that Interferon IFN β-1a given with or without lopinavir/ritonavir, respectively 1412 and 651 patients, did not provide any survival benefit vs control in hospitalized patients (HR 1.16 (0.96-1.39)) (41). The results of the DisCoVeRy trial have been published, including a lopinavir/ritonavir interferon β-1a arm (135). There was no impact on clinical outcomes. Inclusion in the study arm was stopped prematurely due to futility.

Several smaller RCTs have looked at IFN β-1a, in addition to SOC including lopinavir/ritonavir, in severe COVID-19 and could not find a clinical benefit (134,136,137). A recent Indian multicenter open label RCT evaluated a single dose of Pegylated interferon α2b in moderate COVID-19 with only modest clinical improvement and viral clearance (138).

At this moment one small, underpowered RCT looked at the effect of combination of inhaled interferon β-1b and Favipiravir vs standard of care with hydroxychloroquine in severe COVID-19, finding no effect (139). Another pilot double-blind placebo RCT found that hospitalized COVID-19 patients treated with 14 days of nebulized interferon β-1a had a greater odds for clinical improvement (140). No data were available on additional therapies used in these patients.

Available evidence in the ambulatory setting: Recently two small studies have looked at the effect of early single dose administration of peginterferon-lambda on viral clearance in outpatients with COVID-19 and found opposing results (141,142). A few studies have looked at IFN administration by spray or atomization, to improve local effects and avoid systemic adverse reactions (143,144).

Further studies are needed to clarify the role of Interferons in the treatment of COVID-19.

2.8. CHLOROQUINE AND HYDROXYCHLOROQUINE

Main message: Current high-quality evidence demonstrates that hydroxychloroquine (HCQ) does not improve clinical outcomes among COVID-19 infected patients. It has been decided since the beginning of June 2020 (version 10) not to recommend its off-label use for COVID-19 in Belgium anymore. In December 2020, the WHO recommended against the use of (hydroxy-)chloroquine in clinical care regardless of COVID-19 severity.

Available evidence in the hospital setting: Chloroquine and hydroxychloroquine initially appeared promising because it could inhibit replication of SARS-CoV-2 in vitro (145).

The role of hydroxychloroquine for treatment of hospitalized COVID-19 patients was assessed in the RECOVERY, SOLIDARITY and DisCoVeRy trials. None of these studies found improved clinical outcomes among treated patients. The prospective RCT RECOVERY in UK stopped enrolling patients on the 5th of June after finding no beneficial effect of high dose hydroxychloroquine (9600 mg in total over 10 days) in patients hospitalized with COVID-19. For the same reason (absence of efficacy in hospitalized patients), the SOLIDARITY trial communicated the suspension of recruitment in the HCQ arm (9600 mg over 10 days) on the 18th of June (link). Similarly, the DisCoVeRy trial stopped enrolling participants in the HCC arm (5600 mg in total over 10 days) at the same period. The results of the large RECOVERY trial on HCQ efficacy in hospitalized COVID-19 patients have shown that mortality at Day 28 was similar in HCQ recipients compared to standard of care (421/1561, 27% versus 790/3155, 25%; p=0.15). No benefit was observed for all secondary outcomes and subgroups of patients (146). Another smaller RCT in Brazil conducted in mild-to-moderate hospitalized
patients did not find any improvement in the clinical status (seven-level ordinal scale) of participants who received HCQ (total dosage: 5600 mg), alone or with azithromycin (500 mg/day for 7 days) (147).

Available evidence in the ambulatory setting: The role of hydroxychloroquine as post-exposure prophylaxis or as early treatment for mild COVID-19 disease was also assessed through additional RCTs, yet no clinical benefit was found. One RCT using HCQ (low-dose) as post-exposure prophylaxis (PEP), showed no prevention of “illness compatible with COVID-19” [40]. This trial had however several limitations such as undocumented treatment adherence and no laboratory confirmation of SARS-CoV-2 infections in 85% of the participants. Another RCT by the same group studied early administration of HCQ in mild/ambulatory patients with laboratory-confirmed or symptomatic contacts (n=423), and no substantial symptom reduction was observed in the HCQ arm compared to masked placebo (148). Here again, many participants (about 40%) were not tested for SARS-CoV2 infection. In a well-designed Spanish RCT evaluating early treatment with HCQ in adults with mild disease (n=293), no clinical (shortening of symptoms) nor viral (reduction of shedding) benefits were observed (149). A cluster-randomized trial by the same Spanish group did not show any reduction in the incidence of SARS-CoV-2 infection nor symptomatic COVID-19 when HCQ was used in post-exposure prophylaxis in healthy persons exposed to a PCR-positive case patient (150).

2.9. LOPINAVIR/RITONAVIR

Main message: Due to lack of evidence for clinical benefit in the SOLIDARITY, RECOVERY and DisCoVeRy trials, lopinavir/ritonavir (LPV/r) is not recommended as a treatment in COVID-19 disease. In December 2020, WHO recommended against the use of LPV/r in clinical care regardless of COVID-19 severity.

Available evidence in the hospital setting: In an RCT, lopinavir/ritonavir (LPV/r 400 mg/100 mg twice daily), initiated more than 12 days after symptom onset (median, IQR 11–17 days), did not show significant clinical benefits in hospitalized patients with COVID-19 (151). Another small RCT conducted in China did not show any viral or clinical benefit either (or at best very marginal) (151). On the 4th of July 2020, the WHO announced that the lopinavir/ritonavir arm was discontinued in the SOLIDARITY trial because of lack of benefit (link). This arm was also stopped in RECOVERY and DisCoVeRy for the same reason. Finally, a benefit risk-assessment performed by the BRAT (Benefit-Risk Action Team) network and published on the 23rd of June 2020, concluded that the benefit-risk profile for lopinavir/ritonavir in severe COVID-19 cannot be considered positive until further efficacy and effectiveness data become available (152). The results of the large RECOVERY trial in hospitalized patients with COVID-19 confirmed that lopinavir/ritonavir had no beneficial effect on mortality at day 28 (374/1616, 23% versus 767/3424, 22%, p=0.60) nor on any secondary endpoint (duration of hospital stay, progression of disease) (153). Results from ongoing clinical trials are still awaited.

Available evidence in the ambulatory setting: No data.

2.10. FAVIPIRAVIR

Main message: Although some encouraging pre-clinical data (mainly in hamster models) have been published, there is currently no evidence from clinical trials concerning the potential utility of this drug for in- or out-patients with COVID-19 infection. This drug is currently unavailable for treatment outside of clinical trials in Belgium.
Available evidence: Favipiravir has a half-cytotoxic concentration (CC50) > 400 μM and the EC50 of favipiravir against SARS-CoV-2 in Vero E6 cells was 61.88 μM/L (much higher than the EC50 of favipiravir for influenza), resulting in a selectivity index (SI) > 6.46 (154). The half-life is approximately 5 hours. Therefore, higher dosing ranges are considered necessary for the treatment of COVID-19 than for influenza (loading dose of 2400mg to 3000mg BID followed by a maintenance dose 1200mg to 1800mg BID) (155). An antiviral effect has been observed in animal models (hamsters) at high dosage (156). This observation has been confirmed in another experiment in Syrian hamsters (157). The combination of favipiravir with molnupiravir (see below) demonstrated a synergetic benefit in the hamster infection model (158).

Available evidence in the hospital setting: An interim analysis of a small phase 2 RCT showed a lower rate of PCR positivity at day 5 post-favipiravir initiation but with no difference at day 10 (159). Another small RCT in India in mild/moderate patients did not find any significant effect on the duration of viral shedding compared to placebo (but a slight reduction in time to clinical cure) (160). A multicentric RCT in Iran did not show any clinical benefit in hospitalized COVID-19 patients treated with favipiravir when compared to LPV/r (161). Also, early administration of favipiravir (1800 mg BID D1 and 800 mg BID till D5) was not associated with any clinical benefit in a large RCT (n=500) among high-risk mild/moderate Malaysian hospitalized patients (162). Large trials are still ongoing.

Available evidence in the ambulatory setting: No data, however it must be noted that in the trials cited above, patients were hospitalized, but some were indeed asymptomatic upon inclusion (159,160,162).

2.11. MOLNUPIRAVIR (LAGEVRIO®)

Main message: Very preliminary studies suggest that this new antiviral drug could be beneficial in early treatment of COVID-19, but no data from RCTs have yet been published.

Molnupiravir is a ribonucleoside analogue with broad antiviral activity including against SARS-CoV-2 in different animal models (ferret, guinea pigs and mouse models) both as prophylaxis and treatment.

Available evidence in the hospital setting: No data. The placebo-controlled, double-blind phase 2 trial (MOVE-IN) in hospitalized patients with confirmed COVID-19 and symptoms onset of 10 or fewer days evaluated different dosage regimens of molnupiravir compared to placebo: 200 mg, 400 mg or 800 mg of molnupiravir twice a day for five days in 304 participants (75 patients received placebo). Median time to recovery was 9 days in all groups, and recovery rates at day 29 were similar as well, ranging from 81.5% to 85.2%. None of the dosage regimens of molnupiravir demonstrated clinical benefit of sustained recovery (163). The Phase 3 trial (MOVE-IN) for hospitalized patients was therefore not initiated for possible futility.

Available evidence in the ambulatory setting: Preliminary phase 1 and phase 2 data suggest the drug is safe and has antiviral activity in humans as well. A phase 3 trial has been concluded (stopped before finishing recruitment, based on the recommendation of the independent Data Monitoring Committee, and in consultation with the U.S. Food and Drug Administration (FDA), due to positive results observed at the interim analysis) in which orally administered 800 mg molnupiravir bd vs placebo was given to non-hospitalized patients at risk of severe disease progression within 5 days of symptom onset (MOVE-OUT trial: NCT04575597). Updated results of the trial showed only a 30% relative risk reduction of hospitalisation and death through 30 days since treatment initiation among 1433 participants. There were 9 deaths in the placebo
group and 1 in the group that received molnupiravir. Furthermore, in the pre-specified sub-group of patients with SARS-CoV2 nucleocapsid antibodies, low viral load, those with diabetes at baseline, several ethnic minorities such as Black, Asian and Native American, and patients enrolled in the Asia-Pacific region showed no positive effect with Molnupiravir treatment, possibly due to small sample sizes (164). Theoretical concerns about long-term mutagenicity, increased risk of inducing SARS-COV-2 variants need to be addressed.

Since the 23rd of November, Lagevrio (molnupiravir) is under evaluation for marketing authorization at EMA. EMA will assess the benefits and risks of Lagevrio in a reduced timeline and could issue an opinion within weeks if the data submitted are sufficiently robust and complete to show the efficacy, safety and quality of the drug.

As of mid-February 2022, this drug is available in Belgium (via emergency use authorization) only for utilization in the nursing home setting in the context of a COVID-19 outbreak, or in the context of a clinical trial. The drug is currently not available for use in the hospital setting, as there is no data showing efficacy of this drug, particularly in special patient populations, and against the omicron variant in hospitalized patients. The little data that is available shows only moderate efficacy to avoid hospitalisations due to COVID-19 when given in the ambulatory setting in patients at risk of disease progression. Practical recommendations concerning the administration of this drug in the nursing home setting can be found in Annex 5.6.

At this stage, *in vitro* experiments do not suggest a modification of the antiviral activity of remdesivir, molnupiravir or nirmatrelvir against BA.1 or BA.2 variants of concern [link](4,49).

### 2.13 NIRMATRELVIR + RITONAVIR (Paxlovid®)

Available evidence: PF-07321332 (nirmatrelvir) is a SARS-CoV-2 protease inhibitor, which blocks the activity of the SARS-CoV-2-3CL protease (M<sup>pr</sup>) and has *in vitro* pan-human coronavirus activity (165). Co-administration with ritonavir slows the metabolism of PF-07321332. In a preprint animal study, in Syrian Golden hamsters, PF-332 (PF-07321332) protected against infection with the beta (B.1.351) and delta (B.1.617.2) SARS-CoV-2 variants (166).

**Available evidence in the hospital setting:** No data.

**Available evidence in the ambulatory setting:**

The EPIC-HR trial is a randomised, double-blind study of non-hospitalised adults with COVID-19 who are at high risk of progression to severe disease. The study was stopped in November 2021 due to the demonstrated efficacy of Paxlovid® in the interim analysis. In the final analysis of the EPIC-HR trial, 5/697 (0.7%) of patients who received PAXLOVID within 3 days of symptoms onset were hospitalised up to day 28 post-randomisation (hospitalized, 0 death), compared to 6.5% of patients who received placebo (44/682 hospitalised with 9 deaths), resulting in a risk reduction of 89% (p<0.0001). The incidence of adverse events was similar in both groups. Note that exclusion criteria in the study included the use of a drug that was highly dependent on CYP3A4 during treatment and for 4 days after the last dose of PF-07321332/ritonavir or the use of a potent CYP3A4-inducing drug (167).
The ongoing phase 2/3 study, EPIC-SR (Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients) is evaluating Paxlovid in adults at standard risk and also includes vaccinated patients with acute symptomatic COVID-19 infection (breakthrough infection) who have risk factors for severe disease.

A third ongoing phase 2/3 study, EPIC-PEP (Evaluation of Protease Inhibition for COVID-19 in Post-Exposure Prophylaxis) is evaluating the efficacy of Paxlovid® in post-exposure after contact with a household member.

On December 22, 2021, the FDA issued an EUA for (Paxlovid®) for the treatment of adults and adolescent ≥12 years and ≥40 kg of age with mild to moderate COVID-19 and who are at high risk for progression to severe COVID-19, at the dosage (in patient with no renal impairment) of nirmatrelvir (300 mg) with ritonavir (100 mg) as soon as possible (within 5 days of the onset of COVID-19 symptoms) for 5 days (link).

Since 28 January 2022, Paxlovid® is authorized by EMA for treating COVID-19 high-risk adult patients with no need of supplemental oxygen. The treatment should be administered as soon as possible and within 5 days of symptoms onset (link).

Data concerning real life efficacy of Paxlovid is slowly becoming available. A population-based study on real world data from Israel shows that Paxlovid and adequate vaccination against SARS-CoV2 were associated with significant decrease in the rate of severe COVID-19 or mortality, compared to those not treated, and/or not vaccinated. The study used the database of the largest healthcare provider in Israel, from January and February 2022 when the Omicron variant was circulating. Only adults with positive PCR tests for SARS-CoV2 were included. Of the 180,351 patients included, only 4,737 patients were treated with Paxlovid, and 135,482 (75.1%) had adequate vaccination status. Paxlovid appeared to be more effective in older patients, immunosuppressed patients, and those with underlying cardiovascular or neurological disease (168).

At this stage, in vitro experiments do not suggest a modification of the antiviral activity of remdesivir, molnupiravir or nirmatrelvir against BA.1, BA.2 and BA.4 a/BA.5 variants of concern (link) (4,49).

In the Paxlovid® trial, rebound COVID-19 episodes have been documented both in treated and untreated patients (around 2% in both), including fully vaccinated patients. A brief return of symptoms and PCR positivity might be the natural course of SARS-CoV2 infection. Cases of rebound after treatment with Paxlovid® reported until now are mild and no additional treatment is needed. No resistance to Paxlovid® has been shown. Possible transmission has been reported, so restarting isolation measures as by Sciensano protocol is still required (COVID-19 Rebound After Paxlovid Treatment (cdc.gov).

2.12. CAMOSTAT MESYLATE

Main message: There is no published evidence for clinical efficacy of this drug for COVID-19. This drug is currently unavailable for treatment outside of clinical trials in Belgium.

Available evidence: Camostat mesylate is a serine protease inhibitor used in Japan, which is being evaluated as a repurposed drug after it has shown to reduce SARS-CoV-2 infection of primary human lung cells (Calu-3 cell line) in-vitro (169). Camostat mesylate is under investigation in monotherapy or in combination with either hydroxychloroquine or azithromycin (eg. NCT04355052 (Israel), NCT04321096 (Denmark)).
Available evidence in the hospital setting: The first results of the Danish RCT among 205 hospitalized patients (137 treated with camostat mesylate, 200 mg t.i.d. for 5 days, vs 68 treated with placebo) shows that this drug is safe, but it had no viral nor clinical added benefit compared to standard of care (170).

Available evidence in the ambulatory setting: The results of early treatment in ambulatory patients are still awaited. A phase 2 trial in ambulatory patients looking for antiviral activity is ongoing in UZ Gent (Table 3). Large multi-country trials with clinical endpoints are ongoing and a trial is approved in the ambulatory setting in the KUL.

2.13. FLUVOXAMINE

Main message: Two independent RCTs (one large and one small) and two observational studies have shown that fluvoxamine early treatment is associated with prevention of clinical deterioration in outpatient, at-risk subjects (171,172). The effect on robust clinical endpoints such as hospitalizations or deaths is not fully established, and it is unclear whether it could be beneficial in a fully vaccinated population (with lower baseline risk of complications). For the moment, no strong recommendation can be made for early administration of fluvoxamine or similar drugs in high-risk outpatients. Data on in-hospital patients are scarce, with so far only one observational trial in an ICU population that showed lower overall mortality in the group that received fluvoxamine in addition to standard of care (173). In a meta-analysis that combined the available studies on hospitalized and ambulatory patients, the authors concluded that fluvoxamine had a beneficial effect on mortality or hospitalization rate with an OR of 0.45 (95% CI, 0.28-0.72) (174).

Nevertheless, the quality of studies is poor. Data from RCT are needed before we can recommend this treatment.

Fluvoxamine is a SSRI antidepressant drug but also a strong S1R agonist associated with reduction of inflammation during sepsis. It also has possible anti-platelet activation properties (175).

Available evidence in the hospital setting: An open-label prospective cohort trial with matched controls included 51 COVID-19 patients who met criteria for severe disease and were admitted to the ICU in two university hospitals in Croatia. They were treated with fluvoxamine 100 mg three times daily for 15 days in addition to standard therapy and were prospectively matched for age, gender, vaccination against COVID-19, disease severity and comorbidities with 51 ICU controls. No statistically significant differences between groups were observed regarding the number of days on ventilator support, duration of ICU, or total hospital stay, but overall mortality was lower in the fluvoxamine group, 58.8% (n= 30/51), than in the control group, 76.5% (n= 39/51), HR 0.58, 95% CI (0.36-0.94, p= 0.027) (173).

Available data in the ambulatory setting: A small pilot placebo-controlled trial (n= 80 and n=72 subjects in the fluvoxamine and placebo groups respectively) found a significant difference in the rate of clinical deterioration (0% vs 8%; p=0.009). Dosage used in this pilot trial was 50 mg day 1, then 100 mg BID for 2 days then 100 mg TID until day 15) (176). A larger placebo-controlled trial (TOGETHER) in Brazil (n= 741 and n= 756 in the fluvoxamine and placebo groups, respectively, the vast majority of participants were not vaccinated) found a significant decrease of a composite primary outcome event (hospitalization OR stay > 6h in the emergency room) (10.7% vs 15.7%). In secondary analysis, mortality was also decreased in the per-protocol
fluvoxamine group vs placebo (1 vs 12 deaths), but the difference was not significant in the intent-to-treat population. Dose used was 100 mg BID for 10 days (177).

2.14. AZITHROMYCIN

Main message: Despite some initial interest based on in-vitro data, large clinical trials (e.g. RECOVERY) have not demonstrated improved clinical outcomes among COVID-19 patients (both in and outpatients).

Available data in the hospital setting: Azithromycin, shown to have some antiviral and immunomodulatory effect, has been promoted by some groups based on observational viral and clinical data (178). The potential benefit of using AZM alone or with other drugs has not been demonstrated so far. Two large RCTs in Brazil have explored the usefulness of this drug in association with HCQ, both in mild/moderate (147) and severe hospitalized patients (29), and did not find any added value compared to HCQ alone. The azithromycin arm of RECOVERY was closed on November 27, 2020 for futility, after 2582 patients were randomized to azithromycin and compared to 5182 patients receiving standard of care. No effect was observed on 28-day mortality, nor on the risk of progression to mechanical ventilation or on length of hospital stay (179). The results of DAWN-AZITHRO are also expected soon (Table 3).

Available evidence in the ambulatory setting: No published data.

2.15. IVERMECTIN

Main message: Currently there is insufficient high-quality evidence to justify the use of ivermectin. In line with WHO and EMA, we recommend against the use of ivermectin in clinical care.

Available evidence: In vitro inhibition of SARS-CoV-2 replication in Vero/hSLAM cells9 28 has been reported with ivermectin (IVM), but at concentrations 50 to 100 times higher than those clinically attainable in human patients (150-400 µg/kg). Preliminary evidence based on compilation of observational studies suggested survival benefit in ivermectin recipients (OR, 0.27; 95% CI, 0.09-0.80; P< 0.03) (180).

Available evidence in the hospital setting: No effect was shown on viral clearance, clinical recovery or survival. Please see below.

Available evidence in the ambulatory setting: Until now, 19 (10 double-blinded) RCTs studying the effect of ivermectin at different dosages on viral clearance, prevention, clinical recovery and survival have been published in peer-reviewed journals (180–197). All but two excluded severe and critical COVID-19 patients and dosages of ivermectin varied between 100 µg and 400 µg/kg (single doses up to 5 consecutive days). One trial studied the efficacy of an ivermectin nanosuspension nasal spray (188). Seven of these studies showed a more rapid decline in viral load. None of these studies demonstrated any differences in resolution of symptoms or mortality, except five (two of which non-blinded) RCTs demonstrating significantly less development of symptoms in asymptomatic patients when treated with a single dose of ivermectin (198), more rapid resolution of anosmia (111), less progression to severe illness (199), and more rapid clinical improvement (188,191,199). A recently published systematic review and meta-analysis of RCT’s concluded that ivermectin did not reduce all-cause mortality, length of stay or viral clearance in COVID-19 patients with mostly mild disease (200). Many of the available RCTs show several methodological issues such as small sample size, lack of blinding, various drugs in the control arms, different clinical scenarios (as prophylaxis, early outpatient
administration and later treatment in admitted patients) and/or incomplete data on outcomes, as summarized in a Commentary in British Medical Journal (BMJ) Evidence-Based Medicine (201). Based on the current low to very low evidence, a Cochrane systematic review on ivermectin as treatment or prevention of COVID-19 in in- and outpatients failed to demonstrate its efficacy or safety and does not support its use outside of well-designed RCTs (202). In March 2022, the results of the large TOGETHER platform trial in Brazil demonstrated in a conclusive manner that Ivermectin (400 μg/Kg) daily for 3 days), administered within 7 days of symptom onset in 679 COVID-19 outpatients with at least one risk factor of disease progression, did not reduce the need for hospital admission/ prolonged stay in the emergency department compared to placebo. This trial substantially adds to the body of evidence that Ivermectin is not effective against COVID-19, even when administered early-on in the disease (203).

Of note, a recent correspondence in the N Engl J Med warns about the risks of severe ivermectin toxicity (including ataxia, visual disturbances, convulsions,...leading to hospital admission) when misused at high dosages for treatment or prevention of COVID-19 (204).

2.16. Colchicine

Main message: Preliminary evidence from large trials (RECOVERY) did not find any clinical benefit of this drug for hospitalized COVID-19 patients. Earlier administration in PCR-diagnosed ambulatory patients seemed to provide a marginal benefit in preventing hospital admission in a large RCT (COLCORONA). This must be balanced with the well-known adverse events (diarrhea), the number to treat (70) to prevent one admission and the rather long duration (one month) of the evaluated regimen.

This well-known drug used in several inflammatory diseases has also gained much attention recently. No antiviral activity against SARS-CoV-2 has been demonstrated so far, but its inhibitory action against neutrophil chemotaxis/adhesion and against the inflammasome could be of interest (205).

Available evidence in the hospital setting: For in-hospital patients, evidence remains scarce. A few observational studies using variable drug dosages have been published, suggesting a possible clinical benefit (206). One small open-label RCT has evaluated the efficacy of colchicine for hospitalized patients (one third of the patients however did not require oxygen at inclusion) (207). No patient received corticosteroids as part of SOC treatment. The trial showed a significant reduction in clinical deterioration and an improvement in terms of time to clinical deterioration in the colchicine group. It should be noted that recruitment was terminated prematurely due to slow patient accrual, with 105 of 180 planned inclusions. A second RCT including 75 moderately to severely ill patients (a majority of them also treated with corticosteroids) showed a reduction of the duration of both oxygen supplementation and hospitalization among colchicine-treated patients. ICU admission and death were rare in both groups (208). Two systematic reviews of eight studies (some of them pre-print) with heterogeneous design and varied “control” arms both in out- and inpatients suggested some survival benefit and concluded that large RCTs were still needed. The current evidence does not permit to recommend for or against use of colchicine in the treatment of COVID-19 until data from larger RCTs are published. However, according to the results of an arm of the RECOVERY trial, there was no demonstrated benefit of colchicine in addition to steroids (in terms of mortality at Day 28, duration of hospital stay or progression to mechanical ventilation) in patients hospitalized with COVID-19 (209). A smaller RCT
(n=103) evaluating colchicine in hospital patients reached the same conclusions. These observations strongly suggest that colchicine has no place in patients admitted for severe/critical COVID-19 (210).

**Available evidence in the ambulatory setting:** A large multicenter placebo-controlled RCT evaluated colchicine (2 x 0.5 mg for 3 days followed by 0.5 mg/day for one month) in > 4000 PCR-confirmed COVID-19 ambulatory patients with risk factors for severe covid (being age, main comorbidities, fever or a set of full blood count abnormalities) (211). The trial showed no significant effect of colchicine on the combined primary outcome (death or hospitalization) when considering all included cases (4.7% vs 5.8%, OR 0.79, p=0.081) but showed a reduction of this outcome when considering the prespecified group of PCR-proven cases (4.6% vs 6%, OR 0.75, p=0.042). There were two times more diarrhea in the colchicine group than in the placebo group (13.7 vs 7.3%; p<0.001). The trial was stopped at 75% of planned recruitment, due to organizational constraints. As discussed in the accompanying editorial, these findings do not imply that colchicine will likely become the first-line community treatment for early COVID-19, because the effect size was small, and the number needed to treat large (70). It adds however some evidence that anti-inflammatory drugs administered early in the course of the disease may be beneficial (212).

### 2.17. Aspirin

**Main message:** Aspirin has demonstrated no clinical benefit in two large trials among hospitalized patients across different forms of disease severity and should not be used in the management of COVID-19.

Aspirin (ASA) is a non-selective inhibitor of COX-1 and COX-2 enzymes leading to a decreased production of prostaglandins, thromboxane A2 by platelets. Low dose ASA is associated with antithrombotic effect. In animal models ASA inhibits disseminated intravascular coagulation (DIC) during *Staphylococcus aureus* sepsis through inhibition of platelet activation. Patients with septic shock have decreased risk of DIC when using ASA.

**Available evidence in the hospital setting:** One retrospective study found a decreased risk of mechanical ventilation, ICU admission and in-hospital mortality among patients admitted with COVID-19 (213). Different cohort studies have shown a decreased risk of acute lung injury/ARDS in patients on chronic ASA-treatment.

Dozens of RCTs are evaluating ASA in COVID-19 in addition to standard of care. By press release, RECOVERY trial announced that Aspirin (150 mg daily) has no impact on mortality as compared to standard of care in hospitalized patients ([link](#)). Similar findings were announced for critically ill patients in the REMAP-CAP trials.

**Available evidence in the ambulatory setting:** No data.
2.18. General notes

**Note - ACE inhibitors or ARBs:**

There is currently no evidence from clinical or epidemiological studies that establishes a link between their use and severe COVID-19 (214,215). An RCT found no impact of ACEi/ARB switch in COVID-19 (216). The same types of concerns were raised for non-steroidal anti-inflammatory drugs (NSAIDs), with also no evidence so far to advise for or against these drugs in COVID-19 patients. A nationwide cohort study in Denmark found no difference in COVID-19 outcome in patients with recent use of NSAID (217). However, to be safe, and while waiting pending results, paracetamol may be preferred as first-line symptomatic treatment of pain and fever (at usual dosage), while NSAIDs should be used with caution (as in common practice) and according to common practice (contra-indicated in case of renal failure for example).

**Note - pregnant women:**

Specialized care and close monitoring for complications is absolutely necessary in COVID-19 pregnant women. A COVID positive patient, if maternal condition allows it, can deliver vaginally. Large organizations like WHO, RCOG and ACOG support the practice of breastfeeding even in the context of active SARS-CoV-2 disease, but with application of necessary preventive measures (mask, nipple cleaning, frequent handwashing). See additional guidance on newborns of COVID-19 positive mothers via the following link. Monoclonal antibody treatment of COVID-19 confirmed pregnant women should be considered depending on the safety profile, maternal risk factors (diabetes, hypertension, asthma) and pregnancy outcome (possible risk of premature delivery in the setting of viral infection) (218). International guidelines are available, including from NIH, RCOG and WHO guidance.

The Royal College of Obstetricians and Gynaecologists (RCOG) in the United Kingdom regularly updates its clinical guidance for health professionals and pregnant women regarding COVID-19 in pregnancy.


**Note – children:**

Specific guidelines are available: Traitement et prise en charge de l’enfant atteint de la COVID-19: Particularités pédiatrique/Opvang en behandeling van kinderen met COVID-19 gerelateerde ziekte (online on 1 December 2020):


Note – anticoagulation in COVID-19 patients:

Evidence is emerging that COVID-19 is associated with an increased risk of thromboembolic disease, with pulmonary embolism (as well as cerebrovascular accident or myocardial infarction) regarded as important risk factors for increased mortality. Indeed, an open-label, international, adaptive, multiplatform, randomized, controlled trial where three platform trials were integrated into a single trial (ATTACC, ACTIV-4a, and REMAP-CAP), to evaluate whether therapeutic-dose anticoagulation may improve outcomes in noncritically ill patients hospitalized with COVID-19, compared to usual care thrombo-prophylaxis. 2219 patients were included in the final analysis, when prespecified criteria for superiority of therapeutic-dose anticoagulation were met. Initial therapeutic-dose anticoagulation with heparin increased the probability of survival to hospital discharge (98.6% (adjusted odds ratio, 1.27; 95% credible interval, 1.03 to 1.58), with less use of cardiovascular or respiratory organ support as compared with usual-care thrombo-prophylaxis (219).

On the other hand, an open-label, international, adaptive, multiplatform, randomized, controlled trial where three platform trials were integrated into a single trial (ATTACC, ACTIV-4a, and REMAP-CAP), to evaluate whether therapeutic-dose anticoagulation may improve outcomes in critically ill patients hospitalized with COVID-19, compared to usual care thrombo-prophylaxis. This trial was stopped after 1098 patients were included based on pre-defined criterion for futility for therapeutic-dose anticoagulation. This trial did not result in a greater probability of survival to hospital discharge or a greater number of days free of cardiovascular or respiratory organ support than did usual-care pharmacologic thromboprophylaxis (220).

A consensus guideline on anticoagulation management in COVID-19 positive patients has been published by the Belgian Society on Thrombosis and Haemostasis and available here. Of note, a KCE report on thrombo-prophylaxis in COVID-19 diseases concluded that the BSTH management algorithms are of good quality and in agreement with international guidance.

Note – Oxygen therapy in COVID-19 patients:

A working group coordinated by AFMPS/FAGG has prepared guidelines for oxygen therapy in:

1. Hospitalized patients: FR, NL
2. Patients after hospital discharge and residents of nursery homes: FR, NL

Note – More detailed information on Ambulatory care:

- Treatment of COVID-19 patients in nursing homes: Collège de Médecine Générale : Mise à jour du protocole thérapeutique des résidents d’institutions âgés de plus de 75 ans atteints de Covid-19:

- Superior Health Council advice on Vitamin D, Zinc and COVID-19

- Outpatient care for Covid-19 patients in the context of saturation in Belgian hospitals
3. Summary of efficacy data of selected antiviral drugs

Table 2: Summary of available clinical evidence for treatment with neutralizing monoclonal antibodies (mAb) against SARS-CoV-2 spike protein

<table>
<thead>
<tr>
<th>mAb, Company</th>
<th>Clinical Trial</th>
<th>Study group</th>
<th>Main results</th>
<th>NNT</th>
<th>EMA approval</th>
<th>Available in Belgium</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bamlanivimab</strong></td>
<td>Monotherapy (IV)</td>
<td>BLAZE-1 phase 2 NCT04427501 (71)</td>
<td>Mild to moderate COVID-19, outpatients</td>
<td>Statistically reducing of VL on Day 11 for Ly CoV555 at 2800 mg dose (-0.53 log, p=0.02)</td>
<td>NA</td>
<td>CHMP review 05/03/21 for IV use</td>
</tr>
<tr>
<td>Eli Lilly and Company</td>
<td>Combined with Remdesivir (IV)</td>
<td>ACTIV-3/TICO NCT04501978 (221)</td>
<td>Hospitalised patients without end-organ failure</td>
<td>Efficacy outcomes at Day 5 not statistically significant in the LyCoV555+ remdesivir vs placebo group</td>
<td>NA</td>
<td>Delta and Omicron variant are resistant to bamlanivimab monotherapy (link)</td>
</tr>
<tr>
<td><strong>Bamlanivimab + Etesevimab</strong></td>
<td>Combination therapy (IV)</td>
<td>BLAZE-1 phase 3. NCT04427501 (74)</td>
<td>Mild to moderate COVID-19, outpatients</td>
<td>Statistically reducing of VL on Day 11 for combination treatment (-0.57 log p=0.01)</td>
<td>NA</td>
<td>CHMP review 05/03/21 for IV use</td>
</tr>
<tr>
<td>Eli Lilly and Company</td>
<td>BLAZE-1 phase 3 High Risk patients (75)</td>
<td>Mild to moderate COVID-19, outpatients in high-risk groups</td>
<td>Statistically reduction of hospitalization or death by Day 29 for bamlanivimab 2800 mg + etesevimab 2800 mg group vs placebo Day (relative risk difference, 70%; P&lt;0.001), NNT=20.4)</td>
<td></td>
<td></td>
<td>Beta and gamma and Omicron variant resistant to bamlanivimab + etesevimab (link)</td>
</tr>
<tr>
<td><strong>Casirivimab + imdevimab</strong></td>
<td><strong>Combination therapy (IV)</strong></td>
<td><strong>Phase 2/3</strong></td>
<td><strong>NCT04425629</strong></td>
<td><strong>(77)</strong></td>
<td>Mild to moderate COVID-19, outpatients</td>
<td>Interim analysis: proportion of MAV in REGN-COV2 group through Day 29 (3% vs 6% in the placebo group) and MAV proportion for baseline seronegative patients (6% vs 15% in the placebo group)</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Regeneron Pharmaceuticals, Roche, Ronapreve</td>
<td><strong>Phase 3 portion</strong></td>
<td><strong>NCT04425629</strong></td>
<td><strong>(78)</strong></td>
<td>Mild to moderate COVID-19, high risk outpatients</td>
<td>71.3% (2400mg) and 70.4% (1200mg) reduction in hospitalization and all-cause death by day 29</td>
<td>45.5</td>
</tr>
<tr>
<td></td>
<td><strong>Combination therapy (SC)</strong></td>
<td><strong>Phase 3</strong></td>
<td><strong>NCT04452318 (SC)</strong></td>
<td><strong>(79)</strong></td>
<td>Prevention in household contact positive SARS-CoV-2 (SC)</td>
<td>81.4% risk reduction of a symptomatic infection in the REGN-COV2 (casirivimab 600 mg/imdevimab 600 mg) group compared with placebo (1.5% vs 7.8%) and a shorter time of resolution of symptoms (1.2 vs 3.2 weeks)</td>
</tr>
<tr>
<td></td>
<td><strong>Combination therapy (IV)</strong></td>
<td><strong>Phase 3</strong></td>
<td><strong>RECOVERY trial NCT04381936 (76)</strong></td>
<td>Hospitalised patients</td>
<td>casirivimab 4g and imdevimab 4g, IV + usual care. In seronegative SARS-CoV2, 396 (24%) in the REGEN-COV group and 451 (30%) of usual care died within 28 days (rate ratio 0.80; 95% CI 0.70-0.91; p=0.0010)</td>
<td></td>
</tr>
</tbody>
</table>
| **Sotrovimab**  
(**Xevudy**)<br>GlaxoSmithKline and Vir Biotechnology | Monotherapy  
(IV) | Phase 2-3 COMET-ICE NCT04545060 (83,222) | Mild to moderate COVID-19 in high-risk groups | 85% of reduction of hospitalization or death through Day 29 (1% vs 7%) | 16.7 | No CHMP review 21/05/21 for IV use | EMA authorization 17/12/21 for treatment in adults and adolescents from 12 years of age | Since 17 November, 2021 via government for IV use in mild to moderate COVID-19 (conditional use) |
|---|---|---|---|---|---|---|---|---|
| | Combined with bamlanivimab  
(IV) | BLAZE-4 NCT04634409 Unpublished | Mild to moderate COVID-19 | Unpublished | | | | |
| **Regdanvimab**<br>Celltrion | Monotherapy  
(IV) | Unpublished: link | Adult with mild to moderate COVID-19 | Proportion of hospitalization, oxygen requirement or death by day 28: CT-P59 40 mg/kg: 4.0%  
CT-P59 80mg/kg: 4.9%, pooled CT-P59: 4.4% vs 8.7% in the placebo group | 21.3 | CHMP Review 21/5/2021 for IV use |
| **Tixagevimab/ Cilgavimab**<br>(**EVUSHELD®**<br>AstraZeneca) | Combination Therapy  
(IM) | PROVENT (NCT04625725) (85) | Pre-exposure prophylaxis in Unvaccinated, Seronegative patients | | EMA authorization 24/03/22 for prevention COVID-19 | Available since 20 April 2022, via federal stock |

mAb: monoclonal antibody; NNT: number needed to treat; EMA: European Medicines Agency; IV: intravenous; VL: viral load; NA: not applicable; CHMP: Committee for Medicinal Products for Human use; MAV: medically attended visit; SC: subcutaneous
### Table 3: *In vitro* / *in vivo* efficacy of antiviral drugs selected for treatment of confirmed COVID-19 infection

*Note: all ongoing clinical treatment trials/studies over COVID-19 (> 300) are compiled in a real-time dashboard at LitCovid website, see The Lancet (223); we try to summarize the relevant information for selected drugs.*

<table>
<thead>
<tr>
<th>Drug</th>
<th><em>In vitro</em> activity</th>
<th><em>In vivo</em> activity (animal models)</th>
<th>Clinical studies SARS-CoV-2 (non-exhaustive)</th>
<th>Mechanism of action</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SARS-CoV-1</td>
<td>MERS-CoV</td>
<td>SARS-CoV-2</td>
<td>SARS-CoV-1</td>
</tr>
</tbody>
</table>

**Favipiravir**
- Used in Japan against influenza
- Not studied
- Not studied
- ++ *(145)*
- -
- + *(156)*
- ChiCTR2000029600: Shorter viral clearance time and improved radiological evolution compared to lopinavir /ritonavir (non-randomized) (224)
- Inhibition of the activity of RNA dependent RNA polymerase (RdRp)(225,226)

**Camostat**
- Used in Japan for reflux esophagitis and pancreatitis
- ++ *(169)*
- ++ *(169)*
- ++ *(227)*
- -
- -
- NCT04355052 : recruiting
- NCT04321096 : recruiting
- NCT04353284 : recruiting
- NCT04374019 : recruiting
- Inhibition of TMPRSS2, a cellular serine protease, that primes SARS-CoV-2 Spike (S) protein for cell-entry *(169)*

**Interferons**
- + *(228)*
- + *(228)*
- ++ *(131,229)*
- + *(230)*
- + *(231)*
- - *(41)*
- 3 RCT’s with small number of patients (see text). Further studies needed

*Note: Many other antiviral/immunological treatments have been/are being investigated, including (list not exhaustive) ribavirin, fabiravir, convalescent plasma, monoclonal antibodies, complement inhibitors etc. see Landscape analysis of therapeutics WHO 17/02/2020, link. At this moment, any of these drug candidates should ONLY be evaluated in clinical trials and in Belgium, these trials should ideally be coordinated centrally.*
### 4. Clinical trials in Belgium

For an overview of all currently running clinical trials in Belgium, you can search on [https://databankklinischeproeven.be/](https://databankklinischeproeven.be/) (fill in covid-19 as search term in the ‘medical condition/pathology’ field). Additional trials are currently being set up in Belgium. The table below briefly summarizes only ONGOING trials (already recruiting).

<table>
<thead>
<tr>
<th>PROTOCOL CODE / EudraCT n°</th>
<th>STUDY TYPE</th>
<th>INVESTIGATED PRODUCTS</th>
<th>PATIENT PROFILE</th>
<th>PRINCIPAL INVESTIGATOR/COORDINATING CENTER</th>
</tr>
</thead>
<tbody>
<tr>
<td>COV-AID 2020-001500-41 (completed)</td>
<td>Multicentric, randomized, factorial design, interventional study</td>
<td>Six arms: Anakinra (anti-IL1), Siltuximab (anti-IL6), Tocilizumab (anti-IL6) in monotherapy, double or single combinations; standard of care (SoC)</td>
<td>COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome</td>
<td>B. Lambrecht / UZ Gent</td>
</tr>
<tr>
<td>SARPAC 2020-001254-22 (completed)</td>
<td>Multicentric, randomized, open-label, interventional study</td>
<td>2 arms: Sargramostim (recombinant GM-CSF) vs SoC</td>
<td>Acute hypoxic respiratory failure of COVID-19 patients</td>
<td>B. Lambrecht / UZ Gent</td>
</tr>
<tr>
<td>DAWN – azithro 2020-001614-38 (completed)</td>
<td>Multicentric, randomized, open-label, adaptive, proof-of-concept clinical trial</td>
<td>2 arms: Azithromycin vs SoC (other arms can be included later)</td>
<td>COVID-19 PCR confirmed hospitalized patients</td>
<td>UZ Leuven</td>
</tr>
<tr>
<td>DisCoVeRy Remdesivir arm stopped 2020-000936-23</td>
<td>Multicentric, randomized, open-label, adaptive clinical trial</td>
<td>2 arms: AZD7442 vs SoC</td>
<td>COVID-19 PCR confirmed hospitalized patients</td>
<td>M. Hites / Erasme Hospital UCL St-Luc</td>
</tr>
<tr>
<td>DAWN-plasma (No IMP, therefore no)</td>
<td>Open-label randomized Multicenter</td>
<td>2 arms: convalescent plasma vs SoC</td>
<td>COVID-19 PCR confirmed</td>
<td>G. Meyfroidt/ UZ Leuven</td>
</tr>
<tr>
<td><strong>EudraCT number)</strong></td>
<td>Adaptive design</td>
<td>hospitalized patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td>----------------</td>
<td>-----------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Recruitment is finished</strong></td>
<td>Adaptive design</td>
<td>hospitalized patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>REMAP-CAP 2015-002340-14</strong></td>
<td>Randomized, embedded, multifactorial, adaptive platform trial for community acquired pneumonia, amended for COVID-19</td>
<td>Antiviral therapy: No vs Kaletra Coricosteroid therapy: No vs hydrocortisone 7d vs shock dependent hydrocortisone Immune modulation: No vs interferon-beta-1a vs anakinra (anti-IL1)</td>
<td>COVID-19 PCR confirmed hospitalized patients</td>
<td>AZ Sint-Jan (Brugge), CHU Charleroi, UZ Gent</td>
</tr>
<tr>
<td><strong>DAWN-antico 2020-001739-28A (completed)</strong></td>
<td>Randomized, open-label, adaptive, proof-of-concept clinical trial</td>
<td>3 arms: High prophylactic LMWH +/- anakinra*; Apronin (antifibrinolytic) +/- anakinra*; standard dose of LMWH * anakinra only for patients in hyper-inflammatory stage</td>
<td>COVID-19 PCR confirmed hospitalized patients</td>
<td>UZ Leuven</td>
</tr>
<tr>
<td><strong>Biophytis – BIO101 2020-001498-63</strong></td>
<td>Adaptive design phase 2 to 3, randomized, double-blind, multicentre clinical trial</td>
<td>2 arms: BIO101 (activator of Mas-receptor of the renin-angiotensin system) vs SoC</td>
<td>COVID-19 PCR confirmed hospitalized patients</td>
<td>UCL Namur St Elisabeth AZ St Maarten (Mechelen)</td>
</tr>
<tr>
<td>Study ID</td>
<td>Study Design</td>
<td>Study Details</td>
<td>Intervention</td>
<td>Site(s)</td>
</tr>
<tr>
<td>---------------------</td>
<td>--------------------------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------</td>
<td>------------------------------</td>
</tr>
<tr>
<td>ZILU-2020-002130-33</td>
<td>prospective, randomized, open-label, interventional clinical trial</td>
<td>2 arms: Zilucoplan (inhibitor of complement protein C5) vs SoC</td>
<td>COVID-19 PCR confirmed hospitalized patients</td>
<td>B. Lambrecht/UZ Gent</td>
</tr>
<tr>
<td>OSCAR (GSK) 2020-001759-42</td>
<td>Randomized, double-blind, placebo-controlled clinical trial</td>
<td>2 arms: Otilimab (anti-GM-CSF) vs SoC</td>
<td>Patients with severe pulmonary COVID-19 related disease</td>
<td>GSK</td>
</tr>
<tr>
<td>MOT-C-204 (Inotrem) 2020-001504-24</td>
<td>Randomized, double-blind, placebo-controlled, adaptive, exploratory clinical study</td>
<td>2 arms: Nangibodate iv (TREM1 inhibitor) vs placebo</td>
<td>Mechanically ventilated patients due to COVID-19 and with features of systemic inflammation</td>
<td>UCL St-Luc, ZOL</td>
</tr>
<tr>
<td>TJT2012 2020-002102-58</td>
<td>Prospective open-label P1/2 clinical trial</td>
<td>Mesenchymal stromal cells</td>
<td>Patients with severe COVID-19 requiring supplemental O2</td>
<td>CHU Liège</td>
</tr>
<tr>
<td>ARGX-117-2001 (ArgenX) 2020-001546-19</td>
<td>First-in-human, open-label P1 clinical study</td>
<td>ARGX-117 iv (Humanized antibody that blocks C2b)</td>
<td>COVID-19 hospitalized patients</td>
<td>UZ Gent</td>
</tr>
<tr>
<td>AT-527 (ATEA pharmaceuticals) 2020-002869-34</td>
<td>Randomized, double-blind, placebo-controlled, P2 trial</td>
<td>AT-527 (guanosine nucleotide prodrug) vs placebo</td>
<td>Moderate COVID-19 patients with risk factors for poor outcomes</td>
<td>CHU St-Pierre, AZ St-Maarten (Mechelen)</td>
</tr>
<tr>
<td>ABX464-401 (Abivax) 2020-001673-75</td>
<td>Randomized, double-blind, placebo-controlled, P2/3 trial</td>
<td>ABX464 (antiviral) vs Placebo</td>
<td>Mild-moderate COVID-19 patients with risk factors</td>
<td>UZ Gent, Erasme and CHU Saint-Pierre</td>
</tr>
<tr>
<td>Study Name</td>
<td>Design/Control</td>
<td>Intervention</td>
<td>Population</td>
<td>Sponsor/Location</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>----------------</td>
<td>---------------------------------------------------</td>
<td>-------------------------------------------------</td>
<td>---------------------------------------</td>
</tr>
<tr>
<td>COV-AAT 2020-003475-18</td>
<td>Randomized, placebo controlled, double blind, Phase 2 study</td>
<td>2-arm: Camostat (antiviral, serine protease inhibitor) vs placebo</td>
<td>Ambulatory COVID-19 patients</td>
<td>UZ Gent</td>
</tr>
<tr>
<td>ETHIC trial 2020-003125-39 (completed)</td>
<td>Open label, randomized, P3b trial</td>
<td>2-arm: Enoxaparin vs SoC</td>
<td>Ambulatory COVID-19 patients</td>
<td>F. Cools / Thrombosis Research Institute</td>
</tr>
<tr>
<td>AZD7442 2020-004356-16</td>
<td>Randomized, double blind, placebo controlled, Phase 3 trial</td>
<td>2-arm: AZD 7442 (cocktail of 2 mAb against SARS-CoV-2) Vs Placebo As pre-exposure prophylaxis</td>
<td>Healthy adults</td>
<td>Astra Zeneca</td>
</tr>
<tr>
<td>CONVINCE 2020-002234-32</td>
<td>Open-label, randomized, Phase 4 trial</td>
<td>factorial 2x2 design: Edoxaban and/or colchicine VS No intervention</td>
<td>Ambulatory COVID-19 patients</td>
<td>P Vranckx (Jessaziekenhuis hasselt)</td>
</tr>
<tr>
<td>TRISTARDS (Boehringer Ingelheim) 2020-002913-16</td>
<td>Open label, randomized, sequential, parallel-group, adaptive PIIb/III trial</td>
<td>Alteplase (thrombolyticum) High or low dose + SoC vs SoC alone</td>
<td>Hospitalized patients with ARDS</td>
<td>Erasme Hospital / HOSP St-Pierre</td>
</tr>
<tr>
<td>FITE19 (PTC therapeutics) 2020-001872-13</td>
<td>randomized, double-blind, placebo-controlled, PII/III study</td>
<td>PTC299 (antiviral) Vs placebo</td>
<td>Hospitalized COVID-19 patients</td>
<td>CHU St Pierre / Clinique St Pierre (Ottignies)</td>
</tr>
<tr>
<td>MIT-Co001-C101 2020-003403-33 (completed)</td>
<td>Randomized, double-blind, placebo-controlled, phase 2 trial</td>
<td>Estetrol (E4) + SoC vs placebo + SoC</td>
<td>Hospitalized moderate COVID-19 patients</td>
<td>Erasme Hospital CHR de la Citadelle</td>
</tr>
<tr>
<td>Study</td>
<td>Phase</td>
<td>Design</td>
<td>Intervention</td>
<td>Population</td>
</tr>
<tr>
<td>-------</td>
<td>-------</td>
<td>--------</td>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>C4611001 (Pfizer) 2020-003905-73 (completed)</td>
<td>Phase 1b, 2-part, double blind, placebo controlled</td>
<td>PF07304814 (antiviral) iv vs placebo</td>
<td>Hospitalized moderate COVID-19 patients</td>
<td>Erasme Hospital, CHU Brugmann, Institut Jules Bordet, CHU UCL Namur, C.H.R. de la Citadelle</td>
</tr>
<tr>
<td>PANAMO 2020-001335-28 (completed)</td>
<td>adaptive randomized, double blind, placebo controlled Phase II/III</td>
<td>IFX-1 (immnomodulator: C5a blocker) + SoC vs placebo + SoC</td>
<td>Hospitalized Patients with severe COVID-19 pneumonia</td>
<td>UZA, CHU Dinant Godinne, UCL Namur, Erasme</td>
</tr>
<tr>
<td>DAWN-camostat 2020-005911-27</td>
<td>Randomized, double blind controlled trial phase III</td>
<td>camostat mesylate OR molnupiravir vs placebo</td>
<td>Ambulatory COVID-19 patients</td>
<td>UZ Leuven</td>
</tr>
<tr>
<td>COVID-RESCAP 2020-001714-38</td>
<td>Randomized, placebo controlled, double blind, phase II</td>
<td>RESCAP (bovine alkaline phosphatase) vs placebo</td>
<td>Severe COVID-19 patients with acute respiratory insufficiency</td>
<td>Jesssa Ziekenhuis Hasselt / B. Stessels</td>
</tr>
<tr>
<td>SG018 2020-004743-83 (completed)</td>
<td>Randomized, double-blind, placebo-controlled, phase III</td>
<td>SNG001 (IFN-β1a) vs placebo</td>
<td>Hospitalised moderate COVID-19 patients</td>
<td>CHU Liège – Sart Tilman, AZ Groeninge Kortrijk, CHR Citadelle Liège, CHU Brugmann Brussels</td>
</tr>
<tr>
<td>CV43043 (Roche) 2020-005759-18 (Completed)</td>
<td>Randomized, double-blind, placebo-controlled phase III</td>
<td>RO7496998 (AT-527) vs placebo</td>
<td>Mild to moderate ambulatory COVID-19 patients</td>
<td>3 primary care physicians in BE (Roche: <a href="mailto:global.rochegenentechtrials@roche.com">global.rochegenentechtrials@roche.com</a>)</td>
</tr>
<tr>
<td>HOPECOVID-19 2021-000492-36</td>
<td>Randomized, double-blind, placebo controlled, phase II</td>
<td>Lactavir vs placebo</td>
<td>Ambulatory COVID-19 patients</td>
<td>UCL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>XVR011 (bivalent single domain)</td>
<td></td>
<td>UZ Gent</td>
</tr>
<tr>
<td>Trial Name</td>
<td>Description</td>
<td>Intervention</td>
<td>Outcomes</td>
<td>Location(s)</td>
</tr>
<tr>
<td>------------</td>
<td>-------------</td>
<td>--------------</td>
<td>----------</td>
<td>-------------</td>
</tr>
<tr>
<td>EXEVIR0101 2020-005299-36</td>
<td>FIH, open label, SAD (part 1) Randomised, double blind, placebo controlled (part 2)</td>
<td>antibody fragment vs placebo</td>
<td>Hospitalised mild to moderate COVID-19 patients</td>
<td>CHU de Liège UZ Brussel AZ Sint-Maarten, Mechelen CHU Saint-Pierre</td>
</tr>
<tr>
<td>1487-0003 (BI 767551) 2021-000408-309 (prematurely ended)</td>
<td>Phase III randomized, double-blind, placebo-controlled, parallel-group, group-sequential</td>
<td>BI 767551 (antiviral) Vs placebo</td>
<td>Household contacts to a confirmed SARS-CoV-2 infected individual</td>
<td>Boehringer Ingelheim Pharma</td>
</tr>
<tr>
<td>COV-BARRIER-PEDS 2021-001338-21</td>
<td>Multicenter, Open-Label, Pharmacokinetic and Safety Study</td>
<td>Baricitinib</td>
<td>Pediatric patients from 1 to less than 18 years old hospitalized with COVID-19</td>
<td>Centre Hospitalier Régional de la Citadelle / Eli Lilly (<a href="mailto:EU_Lilly_Clinical_Trials@lilly.com">EU_Lilly_Clinical_Trials@lilly.com</a>)</td>
</tr>
<tr>
<td>EU-SOLID-Act 2021-000541-41</td>
<td>Multicenter, Phase III, double blind, placebo-controlled platform trial</td>
<td>Baricitinib</td>
<td>Hospitalised severe to critical COVI-19 patients</td>
<td>CUB-Erasme, UCL St Luc, UZ Brussel</td>
</tr>
</tbody>
</table>

**Terminated trials**
- Antivirals for COVID-19 2020-001243-15 (itraconazole)
- COVIDAM 2020-001417-21
- SANOFI 2020-001269-35
5. Annexes

5.1. Availability of remdesivir

This annex explains how to access remdesivir. However, since version 21 (July 2021), remdesivir is no longer recommended for the treatment of COVID-19 patients.

The medicine Veklury (remdesivir) is available in the strategic stock, stored and distributed by a State-designated distributor. It is available to hospitals for patients that fill the criteria for use as defined in this guidance. Hospital pharmacists have been informed on the procedure to obtain Veklury.

The FAMHP closely monitors the evolution of stocks and, if necessary, places new order to ensure sufficient supply.

Veklury is registered for the treatment of COVID-19 in adults and adolescents from 12 years of age (with at least a body weight of 40kg). For pregnant women and children <12y, compassionate use is possible (as stated in art 107/1). A request for compassionate use can be sent to https://rdvcu.gilead.com/. When using Remdesivir for compassionate use, a notification to umn@fagg-afmps.be and to the ethics committee of the concerned site is to be made.

If you have problems obtaining the medicinal products in this guideline, please contact supply-problems@fagg-afmps.be

5.2. Safety profiles

Safety profiles can be found at www.BCFI.be (SKPs), www.CBIP.be (RCPs) or via https://geneesmiddelendatabank.fagg-afmps.be/

More information via www.ema.europe.eu (European Medicines Agency)

Any suspected adverse events related to these drugs should be reported through the usual channels, as part of regular pharmacovigilance activities: www.notifieruneffetindesirable.be or https://www.fagg.be/nl/melden_van_een_bijwerkingAls_gezondheidszorgbeoefenaar
5.3. Eligibility criteria for treatment with monoclonal antibodies*

Screening for criteria 1: Laboratory-confirmed, non-severe COVID-19 infection

- SARS-CoV-2 RT-PCR or antigen positive test (self-testing must be confirmed by another test)
- Mild or moderate COVID-19 disease severity**
- Symptom onset <10 days and SARS-CoV-2 positive test <5 days
- Age ≥12 years old

If no to any of the following bullet points: not eligible for mAb treatment

If yes to all bullet points, proceed to next step

Screening for criteria 2: Risk factors for severe COVID-19 disease

- **Immunocompromised**, defined as:
  - Hematological malignancy
  - Solid cancer undergoing treatment
  - Solid organ or hematopoetic stem cell transplantation
  - Primary immune deficiency
  - HIV with CD4 <200/mm³ and/or detectable viral load
  - Prednisolone ≥20mg/day ≥14 days, or other immunosuppressive drugs: see Superior Health Council list of (potentially) immunosuppressive drugs (link)
  - Sickle-cell anemia
  - Major thalassemia
  - Aspleny

OR

- **At least one comorbidity**, defined as:
  - Age ≥65 years old
  - Obesity with BMI ≥30 kg/m²
  - Cardiovascular disease, including uncontrolled hypertension
  - Chronic lung disease, including asthma
  - Type 1 or type 2 diabetes mellitus
  - Chronic kidney disease (eGFR <30 ml/min), including hemodialysis
  - Chronic liver disease (Child Pugh B or C)
  - Chronic neurological disease

If patient has a risk factor (immunosuppression or ≥1 comorbidity), proceed to next step

**Monoclonal antibodies**

- Sotrovimab: not currently recommended for current circulating Omicron subvariants

**Disease severity**

Mild: symptoms of COVID-19 without lower respiratory tract involvement such as dyspnea or abnormal chest imaging

Moderate: clinical or radiological evidence of lower respiratory tract disease and SpO2 ≥ 94% (or no supplemental oxygen required for patients with chronic hypoxia)

Severe: ≥1 of the following:

- Respiratory rate ≥30/min; ≥40/min (children < 5y)
- Blood oxygen saturation ≤93% or need supplemental oxygen
- PaO2/FiO2 ratio <300
- Lung infiltrates >50% of the lung field within 24-48 hours
**Immunocompromised patient:**
- Refer quickly to a hospital to start treatment

**Patient with at least one comorbidity but not immunocompromised:**
- Determine the MASS score and/or Utah score (see synoptic table page 54)
- Patient will be eligible according to the prioritization framework (see page 53)
5.4. PROPOSAL FOR A PRIORITISATION FRAMEWORK REGARDING THE USE OF MONOCLONAL ANTIBODIES (MABS) IN AT-RISK PATIENTS WITH MILD/MODERATE COVID-19 IN BELGIUM

Since May 2021, the mAb therapies are authorized in Belgium for early administration in mild to moderate COVID-19 patients at high risk of complication. Although there was limited availability of mABs in the past, this is currently no longer an issue.

The first mAbs available, casirivimab/imdevimab (REGN-COV2) are currently no longer available and have been replaced by a limited stock of Sotrovimab 500 mg (GlaxoSmithKline) since November 17, 2021.

The current eligibility criteria are rather large (see Annex 5.3), resulting in a risk that availability of mAbs or resources to administer them are insufficient. For this reason, the task force has reflected on a prioritization strategy for both vaccinated and unvaccinated patients at high risk of progression to severe COVID-19. The proposal relies on two scores established in academic reference centers in the US based on emerging observational evidence. Both scores have similarities and slight differences. Since evidence remains very limited, this synoptic Table should only be considered as a guidance to support the decisions of the hospital multidisciplinary committees.

In general, patients reaching the highest scores are those who should benefit most from these therapies (taking also in consideration the short-term prognosis in case of terminal underlying diseases). Cut-offs are provided by the respective research groups for selecting the patients most in need, if resources are limited. The task force feels however that no rigid scoring threshold can be recommended at this stage. As availability and administration capacities increase, selection of patients can become more liberal to provide access to a larger group of high-risk patients.

The decision to administer a mAB to a patient should also be guided by the dominant circulating variants in Belgium at the given time. If the mAB available does not show in-vitro activity against the circulating variant, other treatment options should be prioritized (e.g. nirmatrelvir+ritonav, remdesivir, or molnupiravir). These treatments are currently only available for severely immunocompromised patients.
### Synoptic Table summarizing both scoring systems (Mayo Clinic (66) & Utah (link)):

<table>
<thead>
<tr>
<th>Criteria/Comorbidities*</th>
<th>Score Mayo Clinic (MASS)</th>
<th>Score Utah</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total = 20</td>
<td></td>
<td>Total = 38.5</td>
</tr>
<tr>
<td>Age &gt; 100 years</td>
<td></td>
<td>5.5</td>
</tr>
<tr>
<td>Age 91-100 years</td>
<td></td>
<td>5</td>
</tr>
<tr>
<td>Age 81-90 years</td>
<td></td>
<td>4.5</td>
</tr>
<tr>
<td>Age 71-80 years</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Age 61-70 years</td>
<td>2</td>
<td>3.5</td>
</tr>
<tr>
<td>Age 50-60 years</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>BMI ≥ 30 kg/m²</td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>BMI ≥ 35 kg/m²</td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>End-stage kidney disease</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>End-stage liver disease</td>
<td>(not mentioned)</td>
<td>1</td>
</tr>
<tr>
<td>Cardiovascular disease</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Arterial hypertension</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Active cancer</td>
<td>not mentioned</td>
<td>1</td>
</tr>
<tr>
<td>Chronic respiratory disease</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Immunosuppression (of any type)</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Genetic/congenital disorder</td>
<td>Case by case discussion</td>
<td>No score attributed</td>
</tr>
<tr>
<td>Chronic neurologic disease</td>
<td>(not mentioned)</td>
<td>1</td>
</tr>
<tr>
<td>Pregnancy</td>
<td>Case by case discussion</td>
<td>No score attributed</td>
</tr>
<tr>
<td>New shortness of breath</td>
<td>not mentioned</td>
<td>1</td>
</tr>
</tbody>
</table>

* Interpretation:

- **For the Mayo Clinic guideline**, in case of scarce resources, mAbs should be given in priority to patients with MASS ≥ 4 (admission rate was significantly lower in the local experience, for a number to treat between 3 and 8).

  Limitations: there is no clear distinction between vaccinated and unvaccinated patients, and no guidance is provided for pregnant women.

- **For the Utah guideline**, in case of scarce resources, mAbs should be given in priority to patients:
  - If severely immunocompromised: patient is eligible, regardless of score
  - If NOT fully vaccinated, and ≥ 75 years of age: patient is eligible, regardless of score
  - If fully vaccinated: score ≥ 8
  - If NOT fully vaccinated: score ≥ 6
  - If NOT fully vaccinated AND pregnant: ≥ 4

  Limitation: no internal validation data have been published so far.
5.5. MABS ORDER FORM

Imbedded in this document is the Xevudy® (sotrovimab) order form. This form can be filled in and sent to strategicstock@medista.be to order stock from Medista (link).
5.6 MOLNUPIRAVIR (LAPEVRI®) IN THE NURSING HOME SETTING WHEN THERE IS A COVID-19 OUTBREAK:

As of mid-February 2022, this drug is available in Belgium (emergency use authorization) only for utilization in clinical trials, or in the case of an outbreak in the nursing home setting, and only if certain patient information is provided to the AFMPS/FAGG. The little data that is available shows only moderate efficacy to avoid hospitalizations due to COVID-19 when given in the ambulatory setting in patients at risk of disease progression. The drug is easy to administer because it is given orally, and there are no drug-to-drug interactions currently identified. Furthermore, dosage regimens do not need to be adapted to altered hepatic or renal functions.

Indication for use:
1. Symptomatic (mild or moderate disease) in adult patients (≤ 5 days) at risk for COVID-19 disease progression, AND
2. PCR-confirmed SARS-CoV2 infection AND
3. ≥ 18 years old AND
4. Negative pregnancy test if female, and of child-bearing age (a reliable contraception should be taken during the entire duration of therapy, until 4 days after completing treatment with Molnupiravir) AND
5. Nursing home or hospital outbreak setting
6. Patients with contra-indications to receive other antivirals against SARS-CoV2 (primarily, severe renal insufficiency)

Contra-indications:
1. Lactating patients
2. Pregnant patients
3. Pre-exposure or post-exposure prophylaxis
4. Severe or critical COVID-19 disease
5. Uncontrolled HIV positive patients
6. Immunocompromised patients (other than by age) that could benefit from the administration of another more effective antiviral drug.

Drug dosage:
- 800 mg (=4 capsules of 200 mg) every 12 hours for maximum of 5 days
- No drug interactions are currently identified
- No dosage adjustments are recommended in
  - geriatric patients,
  - patients with renal impairment or
  - patients with hepatic impairment

N.B. Sexually active men should use effective contraception until 3 months after the last dose of molnupiravir.
5.7 ADMINISTRATION OF EVUSHELD® FOR PROPHYLAXIS

COVID-19 vaccination provides strong protection against severe disease and the need for hospitalization in most patient populations. However, in the severely immunocompromised patient population, or in dialysis patients, insufficient immunological protection is provided by vaccination against SARS-CoV2.

Several studies have attempted to establish a correlate of immune protection of the different COVID-19 vaccine platforms, without currently being able to reach a consensus (232–234).

We propose to use a threshold value of anti-Spike Ig binding antibody to prioritize severely immunocompromised patients in whom a benefit from Evusheld is expected. The antibodies should be measured at least 2-4 weeks after the last booster vaccine, unless patients have received within the last year, or are currently receiving lymphocyte B depleting therapies. In this case, no antibodies need to be measured.

It should be noted that these studies were performed before the period of circulation of the Omicron variant. Therefore, the studies on efficacy may not reflect the current situation. An adaptation of this threshold may occur in the future depending on new data concerning the new VOCs (Omicron BA.1, BA.2, BA.4 and BA.5...).

In patients who have received in the past year, or are still receiving lymphocyte B depleting therapies, or patients who are non-responders to vaccination (those with an antibody level anti-S < 260 BAU/mL (232,233) a prophylactic treatment with EVUSHELD® can be proposed. The antibodies should be measured at least 2-4 weeks after the last booster vaccine.

Evusheld® should be administered at least 15 days after the last vaccination dose received against SARS-CoV2.

A PCR test for SARS-CoV2 is no longer required before administering the drug. EVUSHELD® should be administered in the hospital setting, as 2 separate sequential intramuscular injections (150 mg each). If the patient remains immunosuppressed, a new dose of EVUSHELD® can be administered 6 months later.

If the patient develops COVID-19, within 6 months of having received EVUSHELD®, the infection should be documented, and the virus strain should be sent to the National Reference Center at UZ Leuven.
The procedure for the delivery and administration of Evusheld is available on the KCE link.

For the future, the utilization of EVUSHELD® for prophylaxis will depend on its’ efficacy against circulating variants.

**Indications:** Adults or children > 12 years of age AND
- ≥ 40 Kgs AND
- Severely Immunocompromised patients, defined as:
  - Hematological malignancy
  - Solid cancer undergoing cytotoxic treatment
  - Solid organ or hematopoetic stem cell transplantation
  - Patients who are within 1 year of receiving B-cell depleting therapies (e.g. rituximab, ocrelizumab, alemtuzumab, etc.)
  - Primary immune deficiency
  - HIV with CD4 <200/mm³ and/or detectable viral load
  - Chimeric antigen receptor T cell recipients (CAR-T cell therapy)
    - Patients treated with immunosuppressive drugs such as anti-proliferatives (azathioprine, mycophenylate mofetil), calcineurin inhibitors (tacrolimus, cyclosporine, etc.), CTLA-4 agonists (abatacept), JAK inhibitors (baracitinib, ruloxitinib, tofacitinib, etc).

(link to Superior Health Council definitions of severely immunocompromised patients)
5.8 PROPOSAL FOR PRACTICAL ASPECTS CONCERNING ADMINISTRATION OF PAXLOVID® (NIRMATRELVIR+RITONAVIR)

Since 28 January 2022, Paxlovid® is authorized by EMA for treating COVID-19 high-risk adult patients with no need of supplemental oxygen. Although authorized for use by the EMA, clinicians should be aware of several limitations. First, ritonavir is a strong cytochrome P450 3A4 inhibitor, causing many drug-drug interactions. Second, there is almost no data on the efficacy of this drug in immunocompromised patients, or in patients taking drugs that could cause drug-drug interactions with ritonavir. Indeed, the EPIC-HR trial was stopped early due to the demonstrated efficacy of Paxlovid® in the interim analysis, and exclusion criteria in the study were the use of any drug that was highly dependent on CYP3A4 during treatment and for 4 days after the last dose of nirmatrelvir/ritonavir, or the use of a potent CYP3A4-inducing drug (167). Third, the drug cannot be administered to patients with renal insufficiency with a creatinine clearance < 30 mL/minute, or those with severe hepatic insufficiency.

Nevertheless, severely immunocompromised patients continue to be hospitalized for COVID-19, due to insufficient immunological protection provided by vaccination against SARS-CoV2. Furthermore, sotrovimab (the mAB currently available for treatment of patients at high-risk for COVID-19 disease progression) shows significantly less in-vitro neutralizing activity against the current circulating variant (BA.2). In this light, Paxlovid has become one of the recommended therapies, based on low-quality evidence (other option: remdesivir IV for 3 days, or Molnupiravir (only if creatinine clearance < 30 mL/minute) for immunosuppressed patients who develop COVID-19. The treatment should be administered as soon as possible, and definitely within 5 days of symptoms onset (link).

Severely Immunocompromised Patients:

- Hematological malignancy
- Solid cancer undergoing cytotoxic treatment
- Solid organ or hematopoietic stem cell transplantation
- Patients who are within 1 year of receiving B-cell depleting therapies (e.g. rituximab, ocrelizumab, alemtuzumab, etc.)
- Primary immune deficiency
- HIV with CD4 <200/mm³ and/or detectable viral load
- Patients chronically treated with corticosteroids > 20 mg of prednisolone or equivalent per day
- Patients chronically treated with methotrexate > 20 mg/week
- Chimeric antigen receptor T cell recipients (CAR-T cell therapy)
- Patients treated with immunosuppressive drugs such as anti-proliferatives (azathioprine, mycophenylate mofetil), calcineurin inhibitors (tacrolimus, cyclosporine, etc.), CTLA-4 agonists
Dosage regimen of Paxlovid® in function of creatinine clearance (mL/minute)

<table>
<thead>
<tr>
<th>Creatinine clearance (mL/minute)</th>
<th>Dosage nirmatrelvir (mg)</th>
<th>Dosage ritonavir (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 60</td>
<td>300 BID</td>
<td>100 BID</td>
</tr>
<tr>
<td>≥ 30 to &lt; 60</td>
<td>150 BID</td>
<td>100 BID</td>
</tr>
<tr>
<td>&lt; 30</td>
<td>Contra-indicated</td>
<td>Contra-Indicated</td>
</tr>
</tbody>
</table>

Proposition of how to handle drug-drug interactions ([link](#) for NIH guidelines)

<table>
<thead>
<tr>
<th>Concomitant medications requiring patients to receive an alternative COVID-19 therapy. This list is not exhaustive.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Here is a list of the contra-indicated drugs provided by the <a href="#">EMA</a>.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Concomitant medications that should be temporarily withheld, if clinically appropriate. Drug monitoring may be required. This list is not exhaustive.</th>
</tr>
</thead>
</table>
| Amiodarone  
Carbamazepine  
Ergot derivatives  
Flecainide  
Midazolam  
Phenobarbital  
Phenytoin  |

| Quinidine  
Rifampicin  
Sildenafil (pulmonary hypertension)  
Tadalafil (pulmonary hypertension)  
Vardenafil (pulmonary hypertension)  |

<table>
<thead>
<tr>
<th>Concomitant medications that require dose adjustments/ drug monitoring. This list is not exhaustive. To make dose adjustments, check the Liverpool COVID-19 Drug Interactions website (<a href="#">link</a>).</th>
</tr>
</thead>
</table>
| Atorvastatin  
Clonazepam  
Chemotherapy (kinase inhibitors, vinca alkaloids, BCL-2 inhibitor venetoclax)  
Colchicine  
Diazepam  
Erythromycin  |

| Everolimus  
Rivaroxaban  
Rosuvastatin  
Simvastatin  
Sirolimus  
Tacrolimus  |

| Alprazolam  
Amlodipine  
Clarithromycin  
Digoxin  
Fentanyl  
Itraconazole  
Ketoconazole  |

| Oxycodone  
Rifabutin  
Sildenafil (erectile dysfunction)  
Tadalafil (erectile dysfunction)  
Tamsulosin  
Trazodone  |

For dosage adjustments, please consult:

Pfizer tool:

[https://www.paxlovideducation.be/nl/geneesmiddeleninteractieszoeker](https://www.paxlovideducation.be/nl/geneesmiddeleninteractieszoeker)

Suggestions for dosage adjustments in transplant patients:

[https://www.transplantation-francophone.org/Accueil](https://www.transplantation-francophone.org/Accueil)

6.0 References


74. Gottlieb RL, Nirula A, Chen P. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19 A Randomized Clinical Trial. NEJM. 2021 Jan 21;


Garegnani LI, Madrid E, Meza N. Misleading clinical evidence and systematic reviews on ivermectin for COVID-19. BMJ Evidence-Based Medicine [Internet]. 2021 Apr 22 [cited 2021 May 10]; Available from: https://ebm.bmj.com/content/early/2021/04/21/bmjebm-2021-111678


